[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2289
1. Sheng XR, Matunis EL: Make room for dedifferentiation. Fly (Austin); 2009 Oct-Dec;3(4):283-5
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Make room for dedifferentiation.
  • The reversal of cellular differentiation, or dedifferentiation, has fascinated biologists for many decades.
  • While cells can be re-programmed extensively in culture, examples of in vivo dedifferentiation have recently emerged in both vertebrate and invertebrate systems, allowing for analysis of this intriguing process under more physiologically relevant conditions.
  • Studies suggest that dedifferentiation occurs not only during large-scale cellular regeneration, but also at low levels to replenish stem cells lost due to normal turnover.
  • Our recent paper demonstrates a novel method to induce the dedifferentiation of lineage-committed stem cell daughters back into germline stem cells (GSCs) in the Drosophila testis.
  • Here, we discuss what our findings reveal about stem cell competition and the capacity of various cell types to dedifferentiate.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cell Dev Biol. 1998 Aug;9(4):433-44 [9813190.001]
  • [Cites] Development. 1996 Aug;122(8):2437-47 [8756289.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16325-30 [17056713.001]
  • [Cites] Cell Stem Cell. 2008 Jan 10;2(1):39-49 [18371420.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):44-54 [18593558.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):725-9 [18698329.001]
  • [Cites] Nature. 2008 Aug 28;454(7208):1132-6 [18641633.001]
  • [Cites] Science. 2009 Jun 26;324(5935):1679-82 [19556501.001]
  • [Cites] Nature. 2009 Jul 2;460(7251):60-5 [19571878.001]
  • [Cites] Science. 2001 Dec 21;294(5551):2542-5 [11752574.001]
  • [Cites] Science. 2001 Dec 21;294(5551):2546-9 [11752575.001]
  • [Cites] Science. 2003 Sep 12;301(5639):1547-50 [12970569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10338-42 [15240884.001]
  • [Cites] J Ultrastruct Res. 1979 Nov;69(2):180-90 [114676.001]
  • [Cites] Artif Organs. 2006 Oct;30(10):743-55 [17026573.001]
  • (PMID = 19923919.001).
  • [ISSN] 1933-6942
  • [Journal-full-title] Fly
  • [ISO-abbreviation] Fly (Austin)
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD052937-05; United States / NICHD NIH HHS / HD / R01 HD052937; United States / NICHD NIH HHS / HD / R01 HD052937-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / STAT Transcription Factors; 0 / bam protein, Drosophila
  • [Other-IDs] NLM/ NIHMS266492; NLM/ PMC3095850
  •  go-up   go-down


2. Zhang Y, Li TS, Lee ST, Wawrowsky KA, Cheng K, Galang G, Malliaras K, Abraham MR, Wang C, Marbán E: Dedifferentiation and proliferation of mammalian cardiomyocytes. PLoS One; 2010 Sep 03;5(9):e12559
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiation and proliferation of mammalian cardiomyocytes.
  • BACKGROUND: It has long been thought that mammalian cardiomyocytes are terminally-differentiated and unable to proliferate.
  • However, myocytes in more primitive animals such as zebrafish are able to dedifferentiate and proliferate to regenerate amputated cardiac muscle.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here we test the hypothesis that mature mammalian cardiomyocytes retain substantial cellular plasticity, including the ability to dedifferentiate, proliferate, and acquire progenitor cell phenotypes.
  • Many dedifferentiated cardiomyocytes went on to express the stem cell antigen c-kit, and the early cardiac transcription factors GATA4 and Nkx2.5.
  • Some, but not all, MDCs self-organized into spheres and re-differentiated into myocytes and endothelial cells in vitro.
  • Cell fate tracking of cardiomyocytes from 4-OH-Tamoxifen-treated double-transgenic MerCreMer/ZEG mouse hearts revealed that green fluorescent protein (GFP) continues to be expressed in dedifferentiated cardiomyocytes, two-thirds of which were also c-kit(+).
  • CONCLUSIONS/SIGNIFICANCE: Contradicting the prevailing view that they are terminally-differentiated, postnatal mammalian cardiomyocytes are instead capable of substantial plasticity.
  • Dedifferentiation of myocytes facilitates proliferation and confers a degree of stemness, including the expression of c-kit and the capacity for multipotency.

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1446-55 [16617123.001]
  • [Cites] Artif Organs. 2006 Oct;30(10):743-55 [17026573.001]
  • [Cites] Cell. 2006 Nov 3;127(3):607-19 [17081981.001]
  • [Cites] Biol Chem. 1999 Dec;380(12):1435-8 [10661871.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):147-55 [11105057.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22772-8 [11274191.001]
  • [Cites] Trends Cardiovasc Med. 2000 Apr;10(3):108-14 [11427997.001]
  • [Cites] Circ Res. 2001 Jul 6;89(1):20-5 [11440973.001]
  • [Cites] Cardiovasc Res. 2001 Aug 1;51(2):230-40 [11470462.001]
  • [Cites] Cardiovasc Res. 2001 Oct;52(1):14-24 [11557230.001]
  • [Cites] J Mol Cell Cardiol. 2001 Dec;33(12):2083-94 [11735256.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Eur Heart J. 2002 Jun;23(11):849-57 [12042006.001]
  • [Cites] Cardiovasc Res. 2002 Jul;55(1):38-52 [12062707.001]
  • [Cites] Cardiovasc Res. 2003 May 1;58(2):423-34 [12757876.001]
  • [Cites] Cell. 2003 Sep 19;114(6):763-76 [14505575.001]
  • [Cites] Mol Interv. 2004 Apr;4(2):81-3 [15087480.001]
  • [Cites] Ann N Y Acad Sci. 2004 May;1015:182-9 [15201159.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):313-28 [15212937.001]
  • [Cites] Circ Res. 2004 Oct 29;95(9):911-21 [15472116.001]
  • [Cites] J Mol Cell Cardiol. 1988 Sep;20(9):825-35 [3230587.001]
  • [Cites] J Biol Chem. 1991 Dec 25;266(36):24613-20 [1722208.001]
  • [Cites] J Mol Cell Cardiol. 1997 May;29(5):1307-20 [9201617.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):169-79 [9202069.001]
  • [Cites] Eur Heart J. 1999 Mar;20(6):406-20 [10213344.001]
  • [Cites] J Cell Physiol. 2005 Mar;202(3):891-9 [15389635.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):326-38 [15690083.001]
  • [Cites] Nature. 2005 Feb 10;433(7026):647-53 [15703750.001]
  • [Cites] PLoS Biol. 2006 Aug;4(8):e260 [16869712.001]
  • [Cites] Microsc Res Tech. 2006 Dec;69(12):983-91 [16972233.001]
  • [Cites] Dev Biol. 2006 Dec 15;300(2):656-69 [17052705.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2007 Feb;4 Suppl 1:S27-39 [17230213.001]
  • [Cites] Circulation. 2007 Feb 20;115(7):896-908 [17283259.001]
  • [Cites] Semin Cell Dev Biol. 2007 Feb;18(1):36-45 [17178459.001]
  • [Cites] Trends Mol Med. 2007 Mar;13(3):125-33 [17257896.001]
  • [Cites] Physiol Rev. 2007 Apr;87(2):521-44 [17429040.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12363-7 [17344217.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 May;292(5):C1799-808 [17229813.001]
  • [Cites] Cell Physiol Biochem. 2007;19(5-6):225-38 [17495463.001]
  • [Cites] J Mol Cell Cardiol. 2007 Jul;43(1):18-26 [17467733.001]
  • [Cites] Prog Cardiovasc Dis. 2007 Jul-Aug;50(1):31-48 [17631436.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):225-32 [17387581.001]
  • [Cites] Nat Med. 2007 Aug;13(8):970-4 [17660827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14068-73 [17709737.001]
  • [Cites] Cell Biol Int. 2007 Nov;31(11):1436-41 [17689109.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1362-8 [18316599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4477-82 [18337493.001]
  • [Cites] Cell Stem Cell. 2008 Mar 6;2(3):219-29 [18371447.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2773-80 [18413744.001]
  • [Cites] Methods. 2008 May;45(1):10-21 [18442701.001]
  • [Cites] Diabetes. 2008 Jun;57(6):1575-83 [18316362.001]
  • [Cites] Circulation. 2008 Aug 5;118(6):649-57 [18645055.001]
  • [Cites] Science. 2009 Apr 3;324(5923):98-102 [19342590.001]
  • [Cites] Methods Mol Biol. 2009;561:91-104 [19504066.001]
  • [Cites] Cell. 2009 Jul 23;138(2):257-70 [19632177.001]
  • [Cites] Nature. 2009 Aug 27;460(7259):1132-5 [19668191.001]
  • [Cites] PLoS One. 2009;4(9):e7195 [19779618.001]
  • [Cites] Regen Med. 2009 Nov;4(6):823-33 [19903002.001]
  • [Cites] Circ Res. 2009 Dec 4;105(12):1164-76 [19959782.001]
  • [Cites] Nature. 2010 Mar 25;464(7288):601-5 [20336144.001]
  • [Cites] Nature. 2010 Mar 25;464(7288):606-9 [20336145.001]
  • [Cites] Trends Mol Med. 2010 Apr;16(4):193-202 [20303826.001]
  • [Cites] Genes Dev. 2005 May 15;19(10):1175-87 [15870258.001]
  • [Cites] Eur J Cell Biol. 2005 Oct;84(10):843-52 [16270752.001]
  • [Cites] Cell Biochem Biophys. 2006;44(1):119-28 [16456240.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9226-31 [16754876.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4585-94 [16532026.001]
  • (PMID = 20838637.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL083109; United States / NHLBI NIH HHS / HL / R01HL083109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / Homeodomain Proteins; 0 / Nkx2-5 protein, mouse; 0 / Nkx2.5 protein, rat; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2933247
  •  go-up   go-down


3. Atkinson DL, Stevenson TJ, Park EJ, Riedy MD, Milash B, Odelberg SJ: Cellular electroporation induces dedifferentiation in intact newt limbs. Dev Biol; 2006 Nov 1;299(1):257-71
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular electroporation induces dedifferentiation in intact newt limbs.
  • Internal cells just proximal to the amputation plane begin to dedifferentiate to form a pool of proliferating progenitor cells known as the regeneration blastema.
  • We show that dedifferentiation of internal appendage cells can be initiated in the absence of amputation by applying an electric field sufficient to induce cellular electroporation, but not necrosis or apoptosis.
  • The time course for dedifferentiation following electroporation is similar to that observed following amputation with evidence of dedifferentiation beginning at about 5 days postelectroporation and continuing for 2 to 3 weeks.
  • We conclude that the application of an electric field sufficient to induce transient electroporation of cell membranes induces a dedifferentiation response that is virtually indistinguishable from the response that occurs following amputation of newt appendages.
  • This discovery allows dedifferentiation to be studied in the absence of wound healing and may aid in identifying genes required for cellular plasticity.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Dec 22;103(7):1099-109 [11163185.001]
  • [Cites] Dev Biol. 1961 Feb;3:26-59 [13712434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1292-7 [11818537.001]
  • [Cites] Biochim Biophys Acta. 2002 Jan 15;1569(1-3):51-8 [11853957.001]
  • [Cites] J Exp Zool. 2002 Feb 15;292(3):255-66 [11857459.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e48 [12000853.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):566-74 [12154368.001]
  • [Cites] Dev Biol. 2004 Jun 1;270(1):135-45 [15136146.001]
  • [Cites] J Morphol. 1966 Jan;118(1):79-89 [5906912.001]
  • [Cites] Dev Biol. 1967 May;15(5):464-86 [6032488.001]
  • [Cites] J Comp Neurol. 1974 Jul 1;156(1):1-18 [4836654.001]
  • [Cites] J Exp Zool. 1974 Dec;190(3):249-68 [4436633.001]
  • [Cites] Nature. 1975 Sep 18;257(5523):224-5 [1161022.001]
  • [Cites] J Embryol Exp Morphol. 1977 Apr;38:151-73 [886241.001]
  • [Cites] J Exp Zool. 1979 Sep;209(3):377-86 [490133.001]
  • [Cites] Differentiation. 1981;20(1):52-60 [6796448.001]
  • [Cites] J Embryol Exp Morphol. 1982 Jun;69:183-92 [7119667.001]
  • [Cites] Biochim Biophys Acta. 1983 Apr 15;739(3):249-57 [6830806.001]
  • [Cites] J Embryol Exp Morphol. 1983 Oct;77:221-41 [6361203.001]
  • [Cites] Nature. 1984 Mar 1-7;308(5954):67-9 [6366572.001]
  • [Cites] J Embryol Exp Morphol. 1984 Dec;84:233-53 [6533251.001]
  • [Cites] Development. 1987 Oct;101(2):267-77 [3446476.001]
  • [Cites] Development. 1990 Apr;108(4):657-68 [1696876.001]
  • [Cites] Dev Biol. 1991 Nov;148(1):219-32 [1718799.001]
  • [Cites] Biophys J. 1992 Nov;63(5):1320-7 [1282374.001]
  • [Cites] Dev Biol. 1996 Sep 15;178(2):251-62 [8812127.001]
  • [Cites] Dev Biol. 2005 Mar 1;279(1):86-98 [15708560.001]
  • [Cites] Dev Dyn. 2005 Jan;232(1):162-70 [15580632.001]
  • [Cites] Int J Legal Med. 2000;114(1-2):66-70 [11197632.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):26087-93 [9748288.001]
  • [Cites] Bioelectromagnetics. 1999;20(3):194-201 [10194562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4262-7 [10200250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13699-704 [11717431.001]
  • (PMID = 16949563.001).
  • [ISSN] 0012-1606
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS043878-02; United States / NINDS NIH HHS / NS / R01 NS043878; United States / NINDS NIH HHS / NS / R01 NS043878-01; United States / NINDS NIH HHS / NS / R01 NS043878-04; United States / NINDS NIH HHS / NS / R01 NS043878-03; United States / NINDS NIH HHS / NS / R01 NS043878S; United States / NINDS NIH HHS / NS / R01 NS043878-03S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS13443; NLM/ PMC1781256
  •  go-up   go-down


Advertisement
4. Kim YD, Kang SM, Min JY, Choi WK, Jeong MJ, Karigar CS, Choi MS: Production of tropane alkaloids during de-differentiation of Scopolia parviflora calli. J Nat Prod; 2010 Feb 26;73(2):147-50
Hazardous Substances Data Bank. SCOPOLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of tropane alkaloids during de-differentiation of Scopolia parviflora calli.
  • The production of tropane alkaloids during differentiation and de-differentiation of Scopolia parviflora calli was studied.
  • Tropane alkaloid production drastically decreased during calli de-differentiation.
  • Scopolamine (1) production decreased after 10 days of culture, whereas that of hyoscyamine (2) decreased during de-differentiation of root to calli.
  • The production of 1 was enhanced in calli undergoing differentiation to shoot after 60 days of culture, reaching a maximum by 80 days.
  • This study suggests that the biosynthesis of tropane alkaloids is regulated inversely in de-differentiating Scopolia parviflora calli.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141164.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tropanes; 451IFR0GXB / Scopolamine Hydrobromide
  •  go-up   go-down


5. Lehti K, Rose NF, Valavaara S, Weiss SJ, Keski-Oja J: MT1-MMP promotes vascular smooth muscle dedifferentiation through LRP1 processing. J Cell Sci; 2009 Jan 1;122(Pt 1):126-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MT1-MMP promotes vascular smooth muscle dedifferentiation through LRP1 processing.
  • At sites of vessel-wall injury, vascular smooth muscle cells (VSMCs) can dedifferentiate to express an invasive and proliferative phenotype, which contributes to the development of neointimal lesions and vascular disorders.
  • Herein, we demonstrate that the loss of the VSMC differentiated phenotype, as the repression of contractile-protein expression, is correlated with a dramatic upregulation of the membrane-anchored matrix metalloproteinase MT1-MMP (also known as MMP14 and membrane-type 1 matrix metalloproteinase).
  • Matrix metalloproteinase (MMP) inhibitors or MT1-MMP deficiency led to attenuated VSMC dedifferentiation, whereas the phenotypic switch was re-engaged following the restoration of MT1-MMP activity in MT1-MMP(-/-) cells.
  • MT1-MMP-dependent dedifferentiation was mediated by the PDGF-BB-PDGFRbeta pathway in parallel with the proteolytic processing of the multifunctional LDL receptor-related protein LRP1 and the dynamic internalization of a PDGFRbeta-beta3-integrin-MT1-MMP-LRP1 multi-component complex.
  • Importantly, LRP1 silencing allowed the PDGF-BB-induced dedifferentiation program to proceed in the absence of MT1-MMP activity, supporting the role of unprocessed LRP1 as a gatekeeper of VSMC differentiation.
  • [MeSH-major] Cell Dedifferentiation / physiology. Matrix Metalloproteinase 14 / metabolism. Muscle, Smooth, Vascular. Myocytes, Smooth Muscle / physiology. Receptors, LDL / metabolism. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066283.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caveolins; 0 / Contractile Proteins; 0 / Lrp1 protein, mouse; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, LDL; 0 / Tumor Suppressor Proteins; 0 / platelet-derived growth factor BB; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


6. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai H, Todo S: Establishment of Immortalized Human Hepatocytes by Introduction of HPV16 E6/E7 and hTERT as Cell Sources for Liver Cell-Based Therapy. Cell Transplant; 2008 Sep;17(9):1083-1094
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intrasplenic transplantation of dedifferentiated HHE6E7T-1 cells over 200 PDs significantly improved the survival of acetaminophen-induced acute liver failure SCID mice.
  • In conclusion, we successfully established immortalized human hepatocytes that retain the characteristics of differentiated hepatocytes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863749.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acetaminophen-induced acute liver failure / Chromosomal instability / Dedifferentiation / Hepatocyte transplantation / Tumorigenicity
  •  go-up   go-down


7. Chaar ZY, Tsilfidis C: Newt opportunities for understanding the dedifferentiation process. ScientificWorldJournal; 2006;6 Suppl 1:55-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newt opportunities for understanding the dedifferentiation process.
  • Particular focus is placed on the dedifferentiation process, which yields a population of embryonic-like pluripotent cells that will eventually reform the lost structure.
  • We discuss the dedifferentiation process in newt forelimb regeneration and outline the various studies that have revealed that mammalian cells also have the ability to dedifferentiate if given the appropriate triggers.
  • [MeSH-minor] Animals. Cell Differentiation. Extremities / anatomy & histology. Extremities / physiology. Mammals / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17205187.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 101
  •  go-up   go-down


8. Yang H, Qian XH, Cong R, Li JW, Yao Q, Jiao XY, Ju G, You SW: Evidence for heterogeneity of astrocyte de-differentiation in vitro: astrocytes transform into intermediate precursor cells following induction of ACM from scratch-insulted astrocytes. Cell Mol Neurobiol; 2010 Apr;30(3):483-91
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for heterogeneity of astrocyte de-differentiation in vitro: astrocytes transform into intermediate precursor cells following induction of ACM from scratch-insulted astrocytes.
  • Our previous study definitely demonstrated that the mature astrocytes could undergo a de-differentiation process and further transform into pluripotential neural stem cells (NSCs), which might well arise from the effect of diffusible factors released from scratch-insulted astrocytes.
  • However, these neurospheres passaged from one neurosphere-derived from de-differentiated astrocytes possessed a completely distinct characteristic in the differentiation behavior, namely heterogeneity of differentiation.
  • The heterogeneity in cell differentiation has become a crucial but elusive issue.
  • In this study, we show that purified astrocytes could de-differentiate into intermediate precursor cells (IPCs) with addition of scratch-insulted astrocyte-conditioned medium (ACM) to the culture, which can express NG2 and A2B5, the IPCs markers.
  • These results revealed that not all astrocytes could de-differentiate fully into NSCs directly when induced by ACM, rather they generated intermediate or more restricted precursor cells that might undergo progressive de-differentiation to generate NSCs.
  • [MeSH-major] Astrocytes / metabolism. Cell Dedifferentiation / physiology. Cell Lineage / physiology. Nerve Regeneration / physiology. Pluripotent Stem Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 Feb 1;22(3):876-85 [11826117.001]
  • [Cites] Glia. 2002 Oct;40(1):25-43 [12237841.001]
  • [Cites] J Neurosci. 2004 Nov 17;24(46):10530-41 [15548668.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):297-306 [11939585.001]
  • [Cites] J Biol Chem. 2008 Mar 28;283(13):8310-7 [18218632.001]
  • [Cites] Glia. 2001 May;34(3):213-28 [11329183.001]
  • [Cites] Biol Cell. 2004 May;96(4):279-90 [15145532.001]
  • [Cites] J Physiol. 2004 Nov 15;561(Pt 1):109-22 [15358811.001]
  • [Cites] J Neurocytol. 1999 Apr-May;28(4-5):365-81 [10739577.001]
  • [Cites] J Neurosci. 2006 Aug 16;26(33):8609-21 [16914687.001]
  • [Cites] J Neurosci Res. 1997 May 15;48(4):299-312 [9169856.001]
  • [Cites] Methods Enzymol. 1990;182:50-68 [2314256.001]
  • [Cites] J Anat. 2005 Dec;207(6):707-16 [16367798.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):169-86 [12682089.001]
  • [Cites] Neuroscience. 2004;128(4):775-83 [15464285.001]
  • [Cites] Neurochem Res. 2008 Nov;33(11):2269-80 [18461449.001]
  • [Cites] J Neurosci Res. 2000 Sep 1;61(5):471-9 [10956416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3996-4001 [9520481.001]
  • [Cites] Cytotechnology. 2006 Oct;52(2):87-97 [19002867.001]
  • [Cites] Glia. 1998 Feb;22(2):161-70 [9537836.001]
  • [Cites] J Cell Biol. 2004 May 24;165(4):575-89 [15159421.001]
  • [Cites] Trends Neurosci. 2001 Jan;24(1):39-47 [11163886.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3061-71 [15241478.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):333-47 [10619551.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):340-53 [17053213.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):2167-75 [15579458.001]
  • [Cites] J Neurocytol. 2002 Jul-Aug;31(6-7):423-35 [14501214.001]
  • [Cites] Glia. 2007 Aug 1;55(10):1001-10 [17503442.001]
  • [Cites] Dev Biol. 1983 Nov;100(1):166-71 [6194025.001]
  • [Cites] Cell Mol Neurobiol. 2009 Jun;29(4):455-73 [19130217.001]
  • [Cites] Dev Genes Evol. 2003 Dec;213(12):625-30 [14608505.001]
  • (PMID = 19885729.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers; 0 / Culture Media, Conditioned; 0 / Gangliosides; 0 / Nerve Tissue Proteins; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4; 0 / ganglioside A2B5; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


9. Zeisberg M, Kramer K, Sindhi N, Sarkar P, Upton M, Kalluri R: De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane. Mol Cell Biochem; 2006 Feb;283(1-2):181-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane.
  • Changes in composition of this ECM are considered detrimental for viability of hepatocytes during progression of liver disease.
  • In order to gain further insights into the role of BM in the regulation of hepatocyte behavior in health and disease, we generated a liver-derived basement membrane matrix (LBLM).
  • Adhesion of primary human hepatocytes to LBLM was increased and the rate of de-differentiation was decreased compared to hepatocyte cultivation on Matrigel or type I collagen matrix.
  • Primary human hepatocytes maintained their differentiated epithelial phenotype on LBLM isolated from normal human livers for more than 21 days, whereas they de-differentiated rapidly on LBLM isolated from cirrhotic human livers.
  • These findings suggest that the composition of liver basement membrane is important for the maintenance of hepatocyte viability and provide anti-de-differentiation clues.
  • [MeSH-major] Basement Membrane / metabolism. Cell Differentiation. Collagen / metabolism. Collagen Type IV / metabolism. Hepatocytes / metabolism. Laminin / metabolism. Liver / metabolism. Liver Cirrhosis / metabolism. Proteoglycans / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 1988 Mar;134(3):309-23 [3350857.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):502-4 [10083210.001]
  • [Cites] Lab Invest. 1995 Dec;73(6):818-27 [8558843.001]
  • [Cites] Biochim Biophys Acta. 1995 Apr 13;1243(3):329-35 [7727507.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):17023-32 [9202017.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1313-21 [11583959.001]
  • [Cites] Biochim Biophys Acta. 1993 Nov 3;1170(3):253-7 [8218343.001]
  • [Cites] Hepatology. 2002 Jun;35(6):1351-9 [12029620.001]
  • [Cites] Toxicol Pathol. 1995 May-Jun;23 (3):326-37 [7659955.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2470-8 [9153291.001]
  • [Cites] Exp Cell Res. 2004 Jan 15;292(2):252-64 [14697333.001]
  • [Cites] Connect Tissue Res. 1992;27(4):225-34 [1576823.001]
  • [Cites] Semin Liver Dis. 2001 Aug;21(3):351-72 [11586465.001]
  • [Cites] J Cell Physiol. 1993 Sep;156(3):522-30 [8360258.001]
  • [Cites] J Cell Biol. 1985 Oct;101(4):1511-22 [4044644.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1195-207 [8132760.001]
  • [Cites] Isr Med Assoc J. 2001 Jan;3(1):44-9 [11344803.001]
  • [Cites] Can J Gastroenterol. 2001 Mar;15(3):187-93 [11264572.001]
  • [Cites] J Biol Chem. 1980 Nov 10;255(21):10451-9 [6776117.001]
  • [Cites] Liver. 1999 Feb;19(1):32-8 [9928763.001]
  • [Cites] Biochemistry. 1980 Jan 8;19(1):169-76 [7352974.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):555-62 [11544023.001]
  • [Cites] Transpl Immunol. 2004 Apr;12(3-4):303-10 [15157923.001]
  • [Cites] Eur J Biochem. 1981 Nov;120(2):203-11 [6274634.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):463-7 [12468248.001]
  • [Cites] Exp Cell Res. 1996 Feb 1;222(2):333-44 [8598222.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2001 Mar;37(3):166-8 [11370807.001]
  • [Cites] Exp Cell Res. 1994 Dec;215(2):332-7 [7526995.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jul 12;295(2):401-7 [12150963.001]
  • [Cites] Nat Methods. 2005 Feb;2(2):119-25 [15782209.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30716-24 [10896941.001]
  • [Cites] Eur J Cell Biol. 2002 Jan;81(1):43-50 [11893078.001]
  • [Cites] J Cell Physiol. 1985 Mar;122(3):333-42 [3881464.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):147-59 [12512039.001]
  • [Cites] Curr Opin Cell Biol. 1993 Dec;5(6):1029-35 [8129940.001]
  • [Cites] J Hepatol. 1998 Apr;28(4):677-90 [9566838.001]
  • [Cites] Eur J Biochem. 1989 Apr 1;180(3):487-502 [2653817.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 3):263-72 [9885280.001]
  • [Cites] Biochemistry. 1982 Nov 23;21(24):6188-93 [6217835.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 5;269(1):46-53 [10694475.001]
  • [Cites] Biochem Biophys Res Commun. 1976 Oct 4;72(3):796-802 [985518.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):15318-24 [1869555.001]
  • [Cites] Histochem Cell Biol. 1997 May;107(5):399-409 [9208331.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2001 May;10(3):315-20 [11342792.001]
  • [Cites] J Clin Invest. 1987 Mar;79(3):801-12 [3546380.001]
  • [Cites] FASEB J. 1995 Nov;9(14):1401-10 [7589981.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2247-50 [10644669.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26033-6 [8253711.001]
  • [Cites] Cell. 1997 Jul 25;90(2):315-23 [9244305.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):674-81 [7833047.001]
  • [Cites] Prep Biochem. 1978;8(2-3):215-24 [568787.001]
  • [Cites] Hepatology. 1992 Jun;15(6):989-97 [1592359.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12719-24 [10777566.001]
  • (PMID = 16444601.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 532TDK07760; United States / NIAAA NIH HHS / AA / AA013913; United States / NIDDK NIH HHS / DK / DK55001; United States / NIDDK NIH HHS / DK / DK62364; United States / NIDDK NIH HHS / DK / DK62987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Collagen Type IV; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


10. Boost KA, Kim HJ, Engl T, Oppermann E, Jonas D, Oertl A, Blaheta RA: c-Met responsiveness of isolated hepatocytes evaluated in an in vitro de-differentiation model. Int J Mol Med; 2006 Mar;17(3):475-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Met responsiveness of isolated hepatocytes evaluated in an in vitro de-differentiation model.
  • However, it remains unclear whether c-Met of de-differentiated hepatocytes adequately responds to HGF in an impaired liver.
  • Therefore, we investigated c-Met expression and c-Met responsiveness to HGF in an experimental de-differentiation cell culture system.
  • Cells were cultivated in a growth factor enriched extracellular milieu (de-differentiation medium), or in a chemically defined differentiation medium, representing physiologically intact hepatocytes. c-Met surface expression was determined by flow cytometry.
  • Hepatocyte-specific asialoglycoprotein receptor (ASGPr) was examined to control the differentiation status of the cells.
  • The addition of bile acids into the culture medium had significantly delayed the process of de-differentiation and restrained the drastic elevation of c-Met (tauroursodeoxycholic acid > ursodeoxycholic acid).
  • [MeSH-major] Cell Differentiation. Cells, Cultured. Hepatocytes / cytology. Hepatocytes / metabolism. Proto-Oncogene Proteins c-met / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465395.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Asialoglycoprotein Receptor; 0 / Culture Media, Serum-Free; 516-35-8 / Taurochenodeoxycholic Acid; 60EUX8MN5X / tauroursodeoxycholic acid; 67256-21-7 / Hepatocyte Growth Factor; 724L30Y2QR / Ursodeoxycholic Acid; 9007-34-5 / Collagen; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


11. Wachter B, Schürger S, Rolinger J, von Ameln-Mayerhofer A, Berg D, Wagner HJ, Kueppers E: Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. Cell Tissue Res; 2010 Nov;342(2):147-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes.
  • Progenitor cells derived from the subventricular zone (SVZ), cells positive for chondroitin sulfate proteoglycan (NG2(+)), and de-differentiated astrocytes have been proposed as the origin of proliferating cells following injury.
  • At 4 days post-lesion, GFAP expression increased markedly.
  • To investigate whether these cells (1) arose from migrating SVZ progenitor cells, (2) derived from NG2(+) progenitor cells, or (3) de-differentiated from resident astrocytes, we studied the expression of the migration marker doublecortin (Dcx), the oligodendrocyte progenitor marker NG2, and the progenitor markers Nestin and Pax6.
  • Thus, resident astrocytes de-differentiate, in response to the intraventricular application of 6-OHDA, to a phenotype resembling radial glia cells, which represent transient astrocyte precursors during development.
  • An understanding of the mechanisms of the de-differentiation of mature astrocytes might be useful for designing new approaches to cell therapy in neurodegenerative diseases such as Parkinson's disease.
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Dedifferentiation / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Glial Fibrillary Acidic Protein / metabolism. Injections, Intraventricular. Ki-67 Antigen / metabolism. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20976472.001).
  • [ISSN] 1432-0878
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenergic Agents; 0 / Biomarkers; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 8HW4YBZ748 / Oxidopamine
  •  go-up   go-down


12. Balsamo M, Romanelli R, Saggino A: The de-differentiation hypothesis in normal elderly persons. Percept Mot Skills; 2010 Feb;110(1):85-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The de-differentiation hypothesis in normal elderly persons.
  • Analysis provided further support for the de-differentiation hypothesis in the Italian population: cognitive abilities differentiate from adolescence to adulthood and then the process is reversed in later adulthood.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391873.001).
  • [ISSN] 0031-5125
  • [Journal-full-title] Perceptual and motor skills
  • [ISO-abbreviation] Percept Mot Skills
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yu T, Cao G, Feng L: Low temperature induced de-differentiation of astrocytes. J Cell Biochem; 2006 Nov 1;99(4):1096-107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low temperature induced de-differentiation of astrocytes.
  • But there is no direct evidence proving that mature astrocytes can de-differentiate into radial glial cells.
  • Here we show that purified astrocytes could de-differentiate into radial glial-like cells (RGLCs) in vitro with freeze-thaw stimulation.
  • These results reveal that low temperature induces astrocytes to de-differentiate into immature RGLCs, which provides an in vitro model to investigate mechanisms of astroglial cells de-differentiation.
  • [MeSH-major] Astrocytes / cytology. Cell Differentiation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767696.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Eye Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins; 0 / Vimentin; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


14. Meng RD, Qin L, Shelton CC, Li Y, Maki RG, Brill ER, Singer S, Schwartz GK: Association of Notch signaling pathway expression in liposarcomas with outcome, and targeting with gamma-secretase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):10526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: RNA was isolated from 18 normal fat and 140 LPS tissue samples from five LPS subtypes: well-differentiated (33%), de-differentiated DD (25%), myxoid (12%), round cell (6%), and pleomorphic (13%), and were hybridized to Affymetrix U133A arrays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ferrari S, Smeland S, Bielack S, Comandone A, Dileo P, Picci P, Sundby Hall K, Eriksson M, Honegger H, Reichardt P: A European treatment protocol for bone sarcoma in patients older than 40 years. J Clin Oncol; 2009 May 20;27(15_suppl):10516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with HG Osteosarcoma (OS), HG sarcoma NOS (S), Fibrosarcoma, MFH, Leiomyosarcoma, Dedifferentiated Chondrosarcoma (DCh) were included.
  • Osteosarcoma and high-grade sarcoma NOS benefit from chemotherapy more than patients with dedifferentiated chondrosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963653.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Spreafico F, Piva L, D'Angelo P, Terenziani M, Collini P, Gandola L, Bianchi M, Tamburini A, Provenzi M, Fossati Bellani F: Are all stage III Wilms tumors the same? Data from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). J Clin Oncol; 2009 May 20;27(15_suppl):10030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 7 patients had intensified chemotherapy/RT for diffuse anaplasia.
  • Overall 16 tumor failure occurred (2 in anaplastic tumors): abdominal relapse 8 (combined to other extra-abdominal site 3), lung 5, tumor progression 2, metacronous tumor 1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ambrosino G, Basso SMM, Varotto S, Zardi E, Picardi A, D'amico DF: Isolated Hepatocytes versus Hepatocyte Spheroids: In Vitro Culture of Rat Hepatocytes. Cell Transplant; 2005 Jul;14(6):397-401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unfortunately, the loss of specialized liver functions (dedifferentiation) is still a major problem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876103.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Albumin / Benzodiazepine / Culture / Hepatocyte spheroids / Isolation / Matrix
  •  go-up   go-down


18. Liu HX, Hu DH, Jia CY, Fu XB: Progress of cellular dedifferentiation research. Chin J Traumatol; 2006 Oct;9(5):308-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress of cellular dedifferentiation research.
  • Differentiation, the stepwise specialization of cells, and transdifferentiation, the apparent switching of one cell type into another, capture much of the stem cell spotlight.
  • But dedifferentiation, the developmental reversal of a cell before it reinvents itself, is an important process too.
  • In multicellular organisms, cellular dedifferentiation is the major process underlying totipotency, regeneration and formation of new stem cell lineages.
  • In humans, dedifferentiation is often associated with carcinogenesis.
  • The study of cellular dedifferentiation in animals, particularly early events related to cell fate-switch and determination, is limited by the lack of a suitable, convenient experimental system.
  • The classic example of dedifferentiation is limb and tail regeneration in urodele amphibians, such as salamanders.
  • Recently, several investigators have shown that certain mammalian cell types can be induced to dedifferentiate to progenitor cells when stimulated with the appropriate signals or materials.
  • These discoveries open the possibility that researchers might enhance the endogenous regenerative capacity of mammals by inducing cellular dedifferentiation in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026865.001).
  • [ISSN] 1008-1275
  • [Journal-full-title] Chinese journal of traumatology = Zhonghua chuang shang za zhi
  • [ISO-abbreviation] Chin. J. Traumatol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor; EC 3.4.21.5 / Thrombin
  • [Number-of-references] 33
  •  go-up   go-down


19. Xie JX, Xu JJ: [Dedifferentiation of mammalian neural cells and its induction]. Sheng Li Ke Xue Jin Zhan; 2009 Apr;40(2):142-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiation of mammalian neural cells and its induction].
  • Dedifferentiation of cells has elicited a great deal of attention in the field of cell biology.
  • A great quantity of studies have proved that many types of cells, such as neuron, Schwann cell, astrocyte, oligodendrocyte, etc., within mammalian nervous system could dedifferentiate in different extent, featured in cell becoming immature, reentering cell cycle and regaining pluripotential.
  • This review concerns on dedifferentiation of various types of cells within mammalian nervous system and inducing conditions, as well as its effect on neural regeneration.
  • [MeSH-major] Cell Dedifferentiation. Nerve Regeneration. Neurons / cytology
  • [MeSH-minor] Animals. Astrocytes / cytology. Cell Differentiation. Mammals. Schwann Cells / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558143.001).
  • [ISSN] 0559-7765
  • [Journal-full-title] Sheng li ke xue jin zhan [Progress in physiology]
  • [ISO-abbreviation] Sheng Li Ke Xue Jin Zhan
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] China
  •  go-up   go-down


20. Yang H, Cheng XP, Li JW, Yao Q, Ju G: De-differentiation response of cultured astrocytes to injury induced by scratch or conditioned culture medium of scratch-insulted astrocytes. Cell Mol Neurobiol; 2009 Jun;29(4):455-73
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-differentiation response of cultured astrocytes to injury induced by scratch or conditioned culture medium of scratch-insulted astrocytes.
  • Our previous reports indicated that astrocytes (ASTs) in injured adult rat spinal cord underwent a process of de-differentiation, and may acquire the potential of neural stem cells (NSCs).
  • However, the AST de-differentiation and transitional rejuvenation process following injury is still largely unclear.
  • The aim of the present study was to determine whether injured in vitro ASTs can re-enter the multipotential-like stem cell pool and regain NSC characteristics, and to further understand the mechanism of AST de-differentiation.
  • Moreover, scratched AST culture supernatant as conditioned cultured medium (ACM) was used to investigate if some diffusible factors derived from injured ASTs could induce de-differentiation of AST.
  • Furthermore, these nestin-immunoreactive ASTs could generate neurospheres, which showed self-renewal and could be differentiated into neurons, ASTs and oligodendrocytes. (2) Scratched ASTs culture supernatant can induce astrocytic proliferation and de-differentiation.
  • These results reveal that the in vitro injured ASTs can de-differentiate into nestin-positive stem/precursor cells, the process of de-differentiation may arise from direct injury or some diffusible factors released from injured ASTs.
  • [MeSH-major] Astrocytes / physiology. Cell Differentiation / physiology. Culture Media, Conditioned / metabolism. Stem Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cell Mol Neurobiol. 2009 Dec;29(8):1105-8 [19472049.001]
  • [Cites] Brain Res. 1999 Sep 4;840(1-2):153-7 [10517963.001]
  • [Cites] Mech Ageing Dev. 2005 Jan;126(1):3-9 [15610756.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Dec;12(6):655-70 [14977475.001]
  • [Cites] Exp Cell Res. 2006 Jul 15;312(12 ):2336-46 [16716298.001]
  • [Cites] J Cell Biochem. 2006 Nov 1;99(4):1096-107 [16767696.001]
  • [Cites] Physiol Behav. 1986;38(6):887-90 [3823208.001]
  • [Cites] Cytobios. 1990;61(246-247):133-60 [2194753.001]
  • [Cites] Biomaterials. 2006 Dec;27(35):5901-8 [16945412.001]
  • [Cites] J Neurosci Methods. 2003 Oct 15;129(1):73-9 [12951234.001]
  • [Cites] Bioessays. 1996 Aug;18(8):639-46 [8760337.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13654-9 [15353594.001]
  • [Cites] Trends Neurosci. 1996 Oct;19(10):422-7 [8888519.001]
  • [Cites] Trends Neurosci. 2002 Aug;25(8):417-22 [12127759.001]
  • [Cites] Trends Pharmacol Sci. 1992 Jul;13(7):286-91 [1509523.001]
  • [Cites] Dev Biol. 2003 Jan 1;253(1):84-98 [12490199.001]
  • [Cites] J Neurosci. 2001 Sep 15;21(18):7153-60 [11549726.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Biol Cell. 2004 May;96(4):279-90 [15145532.001]
  • [Cites] Trends Neurosci. 1996 Aug;19(8):331-8 [8843602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4251-6 [12649319.001]
  • [Cites] Science. 2004 May 28;304(5675):1331-4 [15143218.001]
  • [Cites] Brain Res Mol Brain Res. 1995 Sep;32(2):279-90 [7500839.001]
  • [Cites] Science. 1985 Apr 26;228(4698):497-9 [3872478.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13883-8 [11095732.001]
  • [Cites] Neurochem Res. 2006 Nov;31(11):1381-7 [17053966.001]
  • [Cites] BMC Dev Biol. 2006 Jul 26;6:36 [16872490.001]
  • [Cites] Methods Enzymol. 1990;182:50-68 [2314256.001]
  • [Cites] Brain Res. 1997 Sep 12;768(1-2):1-9 [9369294.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1895-906 [16262629.001]
  • [Cites] Curr Opin Neurobiol. 1995 Oct;5(5):625-35 [8580714.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9387-98 [12417664.001]
  • [Cites] Neuroscience. 2004;128(4):775-83 [15464285.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):707-12 [12447109.001]
  • [Cites] Neurosci Lett. 1991 Jun 10;127(1):70-2 [1715537.001]
  • [Cites] Glia. 2003 Jul;43(1):62-9 [12761868.001]
  • [Cites] Cytotechnology. 2006 Oct;52(2):87-97 [19002867.001]
  • [Cites] NeuroRx. 2004 Oct;1(4):472-81 [15717048.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Jan;244(1):90-5 [15983812.001]
  • [Cites] J Neurosci Res. 2006 Jun;83(8):1515-24 [16612832.001]
  • [Cites] Prog Neurobiol. 2007 Sep;83(1):24-36 [17196731.001]
  • [Cites] Neuroscience. 2006 Sep 29;142(1):287-304 [17120358.001]
  • [Cites] J Neuroimmunol. 1992 Jul;39(1-2):163-73 [1320057.001]
  • [Cites] J Anat. 2007 Jan;210(1):54-65 [17229283.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2061-5 [7892225.001]
  • [Cites] Exp Neurol. 1999 May;157(1):43-57 [10222107.001]
  • [Cites] Trends Neurosci. 1997 Nov;20(11):530-8 [9364668.001]
  • [Cites] Anat Rec. 1999 Aug 15;257(4):137-48 [10467245.001]
  • [Cites] Neurosci Lett. 2007 Jun 21;421(1):22-6 [17548159.001]
  • [Cites] Brain Res Bull. 2001 Sep 1;56(1):37-42 [11604246.001]
  • [Cites] Neuroscience. 1997 Feb;76(4):1121-8 [9027872.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):81-95 [14527435.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):65-79 [14527434.001]
  • [Cites] Curr Top Dev Biol. 2005;69:67-99 [16243597.001]
  • (PMID = 19130217.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin
  •  go-up   go-down


21. Nicolay BN, Bayarmagnai B, Moon NS, Benevolenskaya EV, Frolov MV: Combined inactivation of pRB and hippo pathways induces dedifferentiation in the Drosophila retina. PLoS Genet; 2010 Apr 22;6(4):e1000918
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined inactivation of pRB and hippo pathways induces dedifferentiation in the Drosophila retina.
  • Here, we demonstrate that, independently of cell cycle exit control, in cooperation with the Hippo tumor suppressor pathway, pRB functions to maintain the terminally differentiated state.
  • We show that mutations in the Hippo signaling pathway, wts or hpo, trigger widespread dedifferentiation of rbf mutant cells in the Drosophila eye.
  • Initially, rbf wts or rbf hpo double mutant cells are morphologically indistinguishable from their wild-type counterparts as they properly differentiate into photoreceptors, form axonal projections, and express late neuronal markers.
  • However, the double mutant cells cannot maintain their neuronal identity, dedifferentiate, and thus become uncommitted eye specific cells.
  • Surprisingly, this dedifferentiation is fully independent of cell cycle exit defects and occurs even when inappropriate proliferation is fully blocked by a de2f1 mutation.
  • Thus, our results reveal the novel involvement of the pRB pathway during the maintenance of a differentiated state and suggest that terminally differentiated Rb mutant cells are intrinsically prone to dedifferentiation, can be converted to progenitor cells, and thus contribute to cancer advancement.
  • [MeSH-major] Cell Differentiation. Drosophila / metabolism. Drosophila Proteins / genetics. Intracellular Signaling Peptides and Proteins / genetics. Protein-Serine-Threonine Kinases / genetics. Retina / metabolism. Retinoblastoma Protein / genetics. Signal Transduction. Transcription Factors / genetics

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 20;18(55):7873-82 [10630640.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):328-30 [1406937.001]
  • [Cites] Cell. 2000 Aug 4;102(3):349-62 [10975525.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4533-42 [10970847.001]
  • [Cites] Cell. 2001 Mar 9;104(5):699-708 [11257224.001]
  • [Cites] Cell. 2001 May 4;105(3):345-55 [11348591.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):303-16 [11545733.001]
  • [Cites] Neuron. 2001 Nov 8;32(3):403-14 [11709152.001]
  • [Cites] Cell. 2002 Aug 23;110(4):467-78 [12202036.001]
  • [Cites] Nature. 2003 Feb 27;421(6926):942-7 [12607001.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):223-8 [12853964.001]
  • [Cites] Cell. 2003 Aug 22;114(4):445-56 [12941273.001]
  • [Cites] Cell. 2003 Aug 22;114(4):457-67 [12941274.001]
  • [Cites] Neuron. 1990 May;4(5):697-709 [1693086.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1370-7 [2175046.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):288-94 [1406932.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cell. 1993 Feb 12;72(3):379-95 [8431945.001]
  • [Cites] Nature. 1993 Sep 23;365(6444):349-52 [8377827.001]
  • [Cites] Development. 1994 Aug;120(8):2121-9 [7925015.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1047-57 [8622649.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):467-72 [8636759.001]
  • [Cites] Genes Dev. 1996 Jun 1;10(11):1422-32 [8647438.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3684-92 [8670872.001]
  • [Cites] Cell. 1996 Nov 15;87(4):651-60 [8929534.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1114-8 [15653467.001]
  • [Cites] Dev Cell. 2005 Apr;8(4):541-51 [15809036.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2796-809 [15838516.001]
  • [Cites] Cell. 2005 Aug 12;122(3):421-34 [16096061.001]
  • [Cites] Cell. 2005 Sep 9;122(5):775-87 [16143107.001]
  • [Cites] Development. 2007 Jan;134(2):223-32 [17185323.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):182-91 [17318211.001]
  • [Cites] Dev Cell. 2007 Apr;12(4):631-43 [17419999.001]
  • [Cites] Genes Dev. 2007 Apr 15;21(8):886-97 [17437995.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1081-95 [17574022.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1120-33 [17889654.001]
  • [Cites] Cell. 2007 Oct 19;131(2):378-90 [17956737.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):463-75 [18258751.001]
  • [Cites] Cell. 2008 Feb 22;132(4):567-82 [18295576.001]
  • [Cites] Development. 2008 Mar;135(6):1081-8 [18256197.001]
  • [Cites] Genes Dev. 2008 Apr 15;22(8):1011-24 [18367646.001]
  • [Cites] Development. 2008 Sep;135(17):2827-38 [18697904.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):713-24 [18719710.001]
  • [Cites] Mol Cancer Res. 2008 Sep;6(9):1440-51 [18819932.001]
  • [Cites] PLoS Genet. 2008;4(10):e1000205 [18833298.001]
  • [Cites] Curr Biol. 2008 Oct 14;18(19):1466-75 [18818081.001]
  • [Cites] PLoS Biol. 2007 Jul;5(7):e179 [17608565.001]
  • [Cites] Nat Rev Cancer. 2009 Nov;9(11):785-97 [19851314.001]
  • [Cites] Oncogene. 2006 Aug 28;25(38):5233-43 [16936742.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):210-3 [16906135.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7601-15 [16954388.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2006 Nov-Dec;41(6):339-85 [17092823.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 20421993.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM079774; United States / NIA NIH HHS / AG / AG032169; Canada / Canadian Institutes of Health Research / / grant MOP-93666; United States / NIGMS NIH HHS / GM / R01 GM079774; United States / NCI NIH HHS / CA / CA138631; United States / NCI NIH HHS / CA / R01 CA138631; United States / NIA NIH HHS / AG / F31 AG032169
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Rbf protein, Drosophila; 0 / Retinoblastoma Protein; 0 / Transcription Factors; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / hpo protein, Drosophila
  • [Other-IDs] NLM/ PMC2858677
  •  go-up   go-down


22. Yang JJ, Chen YM, Liu JF, Kurokawa T, Gong JP: Spontaneous redifferentiation of dedifferentiated human articular chondrocytes on hydrogel surfaces. Tissue Eng Part A; 2010 Aug;16(8):2529-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous redifferentiation of dedifferentiated human articular chondrocytes on hydrogel surfaces.
  • Chondrocytes rapidly dedifferentiate into a more fibroblastic phenotype on a two-dimensional polystyrene substratum.
  • This study investigated the redifferentiation behavior of dedifferentiated chondrocytes on a hydrogel substratum.
  • Dedifferentiated normal human articular chondrocyte-knee (NHAC-kn) cells were released from the sixth-passage monolayer cultured on a polystyrene surface.
  • The dedifferentiated NHAC-kn cells spontaneously redifferentiated to normal NHAC-kn cells on neutral (F = 0) and poly(NaAMPS-co-DMAAm) hydrogels of low charge density (F = 0.2).
  • [MeSH-minor] Cell Culture Techniques / methods. Cell Differentiation. Cell Line. Crystallization / methods. Humans. Materials Testing. Surface Properties

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233009.001).
  • [ISSN] 1937-335X
  • [Journal-full-title] Tissue engineering. Part A
  • [ISO-abbreviation] Tissue Eng Part A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Hydrogels
  •  go-up   go-down


23. Chen XW, Jiang P, Gao JH, Liao YJ, Han Z: [Experimental study of human adipocyte dedifferentiation for adipose tissue engineering]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr;29(4):606-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental study of human adipocyte dedifferentiation for adipose tissue engineering].
  • OBJECTIVE: To investigate the dedifferentiation of mature adipocytes and the possibility of adipose tissue engineering using dedifferentiated adipocytes.
  • The cells were cultured in adipogenic, chondrogenic or osteogenic media, and Oil red-O staining, Alcian blue staining and Alizarin red staining were used for dedifferentiation identification.
  • After ceiling adherent culture, the adipocytes underwent morphological changes into fibroblast-like cells indicating their dedifferentiation.
  • The dedifferentiated adipocytes were induced for adipogenic, chondrogenic and osteogenic differentiation in specified media.
  • CONCLUSION: Mature adipocytes can dedifferentiate in vitro culture, and the dedifferentiated adipocytes are capable of differentiating into adipogenic, chondrogenic and osteogenic lineages.
  • Adipose tissue engineering can be achieved in vivo using the dedifferentiated adipocytes as the seed cells.
  • [MeSH-major] Adipocytes / cytology. Cell Dedifferentiation. Tissue Engineering / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403375.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Maki N, Tsonis PA, Agata K: Changes in global histone modifications during dedifferentiation in newt lens regeneration. Mol Vis; 2010 Sep 16;16:1893-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in global histone modifications during dedifferentiation in newt lens regeneration.
  • After lens removal PECs in dorsal iris dedifferentiate and revert to stem cell-like cells, and transdifferentiate into lens cells.
  • The intensity of stained signal in nucleus of PECs was measured and changes in histone modification during dedifferentiation were evaluated.
  • RESULTS: During dedifferentiation of PECs histone modifications related to gene activation were differentially regulated.
  • Although tri-methylated histone H3 lysine 4 (TriMeH3K4) and acetylated histone H4 (AcH4) were increased, acetylated histone H3 lysine 9 (AcH3K9) was decreased during dedifferentiation.
  • Among all gene repression-related modifications analyzed only tri-methylated histone H3 lysine 27 (TriMeH3K27) showed a significant change.
  • CONCLUSIONS: Histone modifications are dynamically changed during dedifferentiation of PECs.
  • A coordination of gene activation-related modifications, increasing of TriMeH3K4 and AcH4 and decreasing of AcH3K9, as well as regulation of TriMeH3K27, could be a hallmark of chromatin regulation during newt dedifferentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cells. 2007 Jan;25(1):2-9 [17023513.001]
  • [Cites] Mech Dev. 2006 Nov;123(11):793-800 [17030116.001]
  • [Cites] Dev Dyn. 2007 Apr;236(4):941-50 [17133523.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):553-60 [17603471.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):286-98 [18371363.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):299-312 [18371364.001]
  • [Cites] Dev Dyn. 2009 Jun;238(6):1613-6 [19384853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19889-94 [19897725.001]
  • [Cites] Nat Rev Genet. 2002 Sep;3(9):662-73 [12209141.001]
  • [Cites] Nature. 2002 Sep 26;419(6905):407-11 [12353038.001]
  • [Cites] Dev Dyn. 2003 Feb;226(2):211-24 [12557200.001]
  • [Cites] Nat Cell Biol. 2004 Jan;6(1):73-7 [14661024.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):838-49 [16261189.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):858-62 [16341014.001]
  • [Cites] Cell. 2007 Feb 23;128(4):707-19 [17320508.001]
  • (PMID = 21031136.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY010540; United States / NEI NIH HHS / EY / EY10540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones
  • [Other-IDs] NLM/ PMC2956703
  •  go-up   go-down


25. Fryd-Versavel G, Lemullois M, Aubusson-Fleury A: Maintaining cell polarity through vegetative cell pattern dedifferentiation: cytoskeleton and morphogenesis in the hypotrich ciliate Sterkiella histriomuscorum. Protist; 2010 Apr;161(2):222-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintaining cell polarity through vegetative cell pattern dedifferentiation: cytoskeleton and morphogenesis in the hypotrich ciliate Sterkiella histriomuscorum.
  • The morphological differentiation of ciliates is achieved through the development of a submembraneous cytoskeleton in which the cilia are anchored.
  • In these species, cells pass through vegetative cell pattern dedifferentiated stages during their biological cycle.
  • Sterkiella exconjugants transiently dedifferentiate to form zygocysts devoid of ciliature and infraciliature.
  • Immunofluorescence images obtained with antibodies directed against pericentrosomal material and tubulin showed that the cells resorb their ciliature and basal bodies, but retain their submembraneous microtubular cytoskeleton during the whole process and that the body plan is maintained through vegetative cell pattern dedifferentiation: the cell polarity remains printed on the cell surface by the microtubular cytoskeleton which in turn could mark the sites of basal body assembly during zygocyst morphogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 20022806.001).
  • [ISSN] 1618-0941
  • [Journal-full-title] Protist
  • [ISO-abbreviation] Protist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tubulin
  •  go-up   go-down


26. Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R: p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis; 2010 Sep;31(9):1501-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.
  • In addition, during the 30 years of p53 research, numerous studies have implicated p53 in the regulation of differentiation and developmental pathways.
  • Here, we summarize the data on these relatively less-characterized functions of p53, including its involvement in embryogenesis and various differentiation programs, as well as its function in restraining de-differentiation of mature somatic cells.
  • Besides the well-known functions of p53 as a cell-cycle regulator and a mediator of apoptosis, both coincide with differentiation processes, p53 was shown to exert its effects on various differentiation programs via direct regulation of specific key factors controlling these programs.
  • The complex regulation by p53, which acts to suppress or to induce differentiation, is mainly the result of the specific cell type and fate.
  • We argue that regulation of differentiation is pivotal for the tumor-suppressive activity of p53, which act to maintain the proper cellular state, preventing improper maturation or reprogramming.
  • This conclusion is further supporting the notion that aberrant differentiation is associated with malignant transformation.
  • [MeSH-major] Cell Differentiation. Cell Proliferation. Neoplasms / metabolism. Tumor Suppressor Protein p53 / physiology

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20504879.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 145
  •  go-up   go-down


27. Yu Y, Feng Z, Wang G, Li F, Du X, Zhu J: Initiation of dedifferentiation and structural changes in in vitro cultured petiole of Arabidopsis thaliana. Protoplasma; 2010 May;241(1-4):75-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initiation of dedifferentiation and structural changes in in vitro cultured petiole of Arabidopsis thaliana.
  • Although the method of tissue culturing has been used widely in practice for a long time, and there are numerous hypotheses to explain the dedifferentiation phenomenon in the tissue culturing, many details of mechanism of dedifferentiation remain unclear.
  • In the study, dedifferentiation process is initiated in the residual procambium, followed by the procambium-derived cells and finally xylem parenchyma cells under the culturing of Arabidopsis thaliana petiole explants.
  • The procambium may induce its derivative cells to undergo dedifferentiation, which in turn induce the xylem parenchyma cells to dedifferentiate.
  • In the present study, only the paired procambium-derived cells and xylem parenchyma truly underwent dedifferentiation, whereas the initial changes in the procambium simply recovered the inherent meristematic capacity of those cells.
  • In transverse section of petiole of A. thaliana, parenchyma cells outside the vascular bundle did not participate in dedifferentiation and gradually disintegrated under the culture conditions.
  • Obviously, the time for initiation and difficulty underlain for undergoing dedifferentiation are dependent on the differential degree and location of parenchyma cells in the petiole.
  • [MeSH-major] Arabidopsis / cytology. Cell Dedifferentiation / physiology. Plant Leaves / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Feb 15;18(4):375-80 [15004006.001]
  • [Cites] Nature. 1970 Jan 10;225(5228):159-64 [5409962.001]
  • [Cites] Nat Protoc. 2006;1(3):1462-7 [17406436.001]
  • [Cites] Cell. 2000 Mar 17;100(6):635-44 [10761929.001]
  • [Cites] Plant Sci. 2006 Oct;171(4):481-7 [25193645.001]
  • [Cites] Cell. 1998 Dec 11;95(6):805-15 [9865698.001]
  • [Cites] Plant Cell Rep. 2008 Sep;27(9):1423-40 [18612644.001]
  • [Cites] Dev Biol. 1989 May;133(1):128-39 [2707480.001]
  • [Cites] Proteomics. 2007 May;7(9):1473-500 [17407188.001]
  • [Cites] Development. 2002 Jul;129(13):3195-206 [12070094.001]
  • [Cites] Trends Biotechnol. 2009 Jun;27(6):329-32 [19395104.001]
  • [Cites] Science. 2005 Oct 28;310(5748):663-7 [16210497.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22772-8 [11274191.001]
  • [Cites] Dev Biol. 2004 Apr 1;268(1):1-6 [15031100.001]
  • [Cites] Genes Dev. 2009 Aug 1;23(15):1791-804 [19651987.001]
  • (PMID = 20127124.001).
  • [ISSN] 1615-6102
  • [Journal-full-title] Protoplasma
  • [ISO-abbreviation] Protoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


28. Real C, Glavieux-Pardanaud C, Le Douarin NM, Dupin E: Clonally cultured differentiated pigment cells can dedifferentiate and generate multipotent progenitors with self-renewing potential. Dev Biol; 2006 Dec 15;300(2):656-69
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonally cultured differentiated pigment cells can dedifferentiate and generate multipotent progenitors with self-renewing potential.
  • The differentiation of a given cell should be irreversible in order to ensure cell-type-specific function and stability of resident tissue.
  • However, under stimulation in vitro or during regeneration, differentiated cells may recover properties of immature cells.
  • Yet the mechanisms whereby differentiated cells can change fate or reverse to precursor cells are poorly understood.
  • We show here that neural crest (NC)-derived pigment cells that have differentiated in quail embryo, when isolated from the skin and clonally cultured in vitro, are able to generate glial and myofibroblastic cells.
  • The phenotypic reprogramming involves dedifferentiation of dividing pigment cells into cells that re-express NC early marker genes Sox10, FoxD3, Pax3 and Slug.
  • These multipotent cells are heterogeneous with respect to marker identity, including pigmented cells and dedifferentiated cells that have reacquired expression of the early NC marker HNK1.
  • [MeSH-major] Cell Differentiation / physiology. Multipotent Stem Cells / cytology

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052705.001).
  • [ISSN] 0012-1606
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Sheng XR, Brawley CM, Matunis EL: Dedifferentiating spermatogonia outcompete somatic stem cells for niche occupancy in the Drosophila testis. Cell Stem Cell; 2009 Aug 7;5(2):191-203
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiating spermatogonia outcompete somatic stem cells for niche occupancy in the Drosophila testis.
  • Differentiating cells can dedifferentiate to replace stem cells in aged or damaged tissues, but the underlying mechanisms are unknown.
  • Here, we establish a system to study spermatogonial dedifferentiation.
  • Ectopically expressing the differentiation factor bag-of-marbles (Bam) removes germline stem cells from the niche.
  • Furthermore, global downregulation of Jak-STAT signaling inhibits dedifferentiation, indicating that normal levels of pathway activation are required to promote movement of spermatogonia into the niche during dedifferentiation, where they outcompete somatic stem cells for niche occupancy.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • FlyBase. FlyBase .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Feb 25;287(5457):1489-93 [10688798.001]
  • [Cites] Science. 2001 Dec 21;294(5551):2542-5 [11752574.001]
  • [Cites] Science. 2001 Dec 21;294(5551):2546-9 [11752575.001]
  • [Cites] Cell. 2001 Dec 28;107(7):831-41 [11779460.001]
  • [Cites] Dev Biol. 2001 Nov 15;239(2):215-28 [11784030.001]
  • [Cites] Genes Dev. 2002 Feb 1;16(3):388-98 [11825879.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4812-21 [12101419.001]
  • [Cites] Genesis. 2002 Sep-Oct;34(1-2):146-51 [12324971.001]
  • [Cites] Artif Organs. 2006 Oct;30(10):743-55 [17026573.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:237-65 [16774460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4633-8 [12676994.001]
  • [Cites] Dev Biol. 2003 Jun 1;258(1):117-28 [12781687.001]
  • [Cites] Science. 2003 Sep 12;301(5639):1547-50 [12970569.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1786-91 [14561403.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:1-22 [14570561.001]
  • [Cites] Dev Cell. 2003 Nov;5(5):787-98 [14602078.001]
  • [Cites] Development. 2004 Mar;131(6):1365-75 [14973292.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):564-9 [15024390.001]
  • [Cites] Dev Cell. 2007 Feb;12(2):195-206 [17276338.001]
  • [Cites] Genetics. 2007 Mar;175(3):1505-31 [17194782.001]
  • [Cites] Science. 2007 Apr 20;316(5823):402-4 [17446390.001]
  • [Cites] Science. 2007 Sep 21;317(5845):1722-6 [17823316.001]
  • [Cites] Cell. 2008 Feb 22;132(4):598-611 [18295578.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):277-85 [18371362.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):470-8 [18371382.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6368-73 [18434551.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):44-54 [18593558.001]
  • [Cites] Eur J Immunol. 2008 Aug;38(8):2060-7 [18651698.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):725-9 [18698329.001]
  • [Cites] Annu Rev Cell Dev Biol. 2008;24:263-86 [18588486.001]
  • [Cites] Cell Stem Cell. 2008 Nov 6;3(5):533-42 [18983968.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):599-604 [18923395.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):190-6 [19098901.001]
  • [Cites] Annu Rev Genet. 1997;31:405-28 [9442902.001]
  • [Cites] Science. 2004 May 28;304(5675):1331-4 [15143218.001]
  • [Cites] Genetics. 2004 Jun;167(2):707-23 [15238523.001]
  • [Cites] Cell Cycle. 2004 Mar;3(3):249-51 [14726648.001]
  • [Cites] J Ultrastruct Res. 1979 Nov;69(2):180-90 [114676.001]
  • [Cites] Genes Dev. 1990 Jun;4(6):905-21 [2384213.001]
  • [Cites] Genes Dev. 1990 Dec;4(12B):2242-51 [2279698.001]
  • [Cites] Mech Dev. 1991 Jun;34(2-3):123-34 [1680377.001]
  • [Cites] Development. 1994 Apr;120(4):947-56 [7600970.001]
  • [Cites] J Cell Biol. 1995 Oct;131(1):165-78 [7559773.001]
  • [Cites] Development. 1995 Sep;121(9):2937-47 [7555720.001]
  • [Cites] Development. 1996 Aug;122(8):2437-47 [8756289.001]
  • [Cites] J Cell Sci. 1996 Dec;109 ( Pt 12):2779-88 [9013326.001]
  • [Cites] Development. 1997 Jan;124(2):271-8 [9053304.001]
  • [Cites] Development. 1997 Sep;124(18):3651-62 [9342057.001]
  • [Cites] Development. 1997 Nov;124(21):4361-71 [9334284.001]
  • [Cites] Development. 1997 Nov;124(21):4383-91 [9334286.001]
  • [Cites] Curr Biol. 1998 Feb 12;8(4):243-6 [9501989.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1183-93 [9657151.001]
  • [Cites] Development. 1998 Aug;125(15):2781-9 [9655801.001]
  • [Cites] Semin Cell Dev Biol. 1998 Aug;9(4):433-44 [9813190.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:605-31 [16212509.001]
  • [Cites] Dev Dyn. 2006 Apr;235(4):958-66 [16477645.001]
  • [Cites] Dev Biol. 2006 Jun 1;294(1):246-57 [16616121.001]
  • [Cites] Development. 2006 Jul;133(14):2605-16 [16794031.001]
  • [Cites] Aging Cell. 2006 Aug;5(4):297-304 [16800845.001]
  • (PMID = 19664993.001).
  • [ISSN] 1875-9777
  • [Journal-full-title] Cell stem cell
  • [ISO-abbreviation] Cell Stem Cell
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD052937-02; United States / NICHD NIH HHS / HD / R01 HD040307-07; United States / NICHD NIH HHS / HD / HD040307-07; United States / NICHD NIH HHS / HD / HD052937-03; United States / NICHD NIH HHS / HD / HD040307-06; United States / NICHD NIH HHS / HD / R01 HD040307-06; United States / NICHD NIH HHS / HD / R01 HD052937-01A1; United States / NICHD NIH HHS / HD / HD040307-08; United States / NICHD NIH HHS / HD / R01 HD040307-05A1; United States / NICHD NIH HHS / HD / R01 HD052937; United States / NICHD NIH HHS / HD / R01 HD040307-09; United States / NICHD NIH HHS / HD / R01 HD040307; United States / NICHD NIH HHS / HD / HD052937-02; United States / NICHD NIH HHS / HD / HD052937-01A1; United States / NICHD NIH HHS / HD / HD040307-05A1; United States / NICHD NIH HHS / HD / HD052937; United States / NICHD NIH HHS / HD / R01 HD052937-03; United States / NICHD NIH HHS / HD / HD040307-09; United States / NICHD NIH HHS / HD / R01 HD040307-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / STAT Transcription Factors; 0 / bam protein, Drosophila; EC 2.7.10.2 / Janus Kinases
  • [Other-IDs] NLM/ NIHMS123000; NLM/ PMC2750779
  •  go-up   go-down


30. Liao YJ, Gao JH, Jiang P, Lu F: [Effect of hypoxia on dedifferentiation of mature adipocytes: an experimental study]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar;28(3):339-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of hypoxia on dedifferentiation of mature adipocytes: an experimental study].
  • OBJECTIVE: To study the morphological changes of mature adipocytes in hypoxic condition in vitro and investigate the effect of hypoxia on dedifferentiation of mature adipocytes.
  • CONCLUSION: Mature adipocytes may dedifferentiate into fibroblast-like cells under appropriate conditions.
  • [MeSH-major] Adipocytes / cytology. Cell Differentiation / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359685.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


31. Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ: Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer; 2006 Nov 15;119(10):2366-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gleason score, age and screening: modeling dedifferentiation in prostate cancer.
  • Tumor differentiation as measured by the Gleason score is highly predictive of the course of prostatic cancer after diagnosis.
  • Since the introduction of the prostate-specific antigen (PSA) test tumors are diagnosed with a favorable tumor stage and differentiation grade.
  • Does screening with PSA just detect more tumors with favorable characteristics or is dedifferentiation actually being prevented by early detection and consequent treatment?
  • The latter option implies that tumors dedifferentiate in the preclinical screen-detectable phase.
  • We fitted 2 MISCAN simulation models to the observed data: Model I where tumors dedifferentiate before becoming screen-detectable and Model II where dedifferentiation occurs during the screen-detectable preclinical phase.
  • The hypothesis of dedifferentiation during the screen-detectable phase was tested by a goodness of fit test of both models.
  • This study provides epidemiological evidence of dedifferentiation as a major mechanism of progression in prostate cancer.
  • Tumors dedifferentiate during the screen-detectable phase and consequently screening with PSA and early treatment can possibly prevent dedifferentiation.
  • [MeSH-minor] Age Distribution. Aged. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Severity of Illness Index


32. Rocker D, Hesse F, Bader A, Wagner R: Intracellular nucleotide pools and ratios as tools for monitoring dedifferentiation of primary porcine hepatocytes in culture. Cytotechnology; 2006 Jul;51(3):119-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular nucleotide pools and ratios as tools for monitoring dedifferentiation of primary porcine hepatocytes in culture.
  • The effect of two culture configurations (single collagen gel and double collagen gel) and of two hormones (insulin and glucagon) on the differentiated status and the intracellular nucleotide pools of primary porcine hepatocytes was investigated.
  • The objective was to analyze and monitor the current state of differentiation supported by the two culture modes using intracellular nucleotide analysis.
  • Specific intracellular nucleotide ratios, namely the nucleoside triphosphate (NTP) and the uridine (U) ratio were shown to consistently reflect the state of dedifferentiation status of the primary cells in culture affected by the presence of the two hormones insulin and glucagon.
  • Continuous dedifferentiation of the cells was monitored in parallel by the reduction of the secretion of albumin, and changes in UDP-activated hexoses and UDP-glucuronate.
  • The presence of insulin maintained the differentiated status of hepatocytes for more than 12 days when cultivated under double gel conditions whereas glucagon was less effective.
  • In contrast, cells cultivated in a single gel matrix immediately started to dedifferentiate upon seeding.
  • NTP and U ratios were shown to be more sensitive for monitoring dedifferentiation in culture than the albumin secretion.
  • Their use allowed the generation of an easily applicable NTP-U plot in order to give a direct graphical representation of the current differentiation status of the cultured cells.
  • Moreover, the transition from functional and differentiated hepatocytes to dedifferentiated fibroblasts could be determined earlier by the nucleotide ratios compared to the conventional method of monitoring the albumin secretion rate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1974 Jan;83(1):186-90 [4855877.001]
  • [Cites] J Biotechnol. 2000 Aug 25;81(2-3):95-105 [10989168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2401-5 [6585805.001]
  • [Cites] J Biomater Sci Polym Ed. 1994;6(4):325-42 [7841142.001]
  • [Cites] Pharmacol Ther. 1994 Oct;64(1):77-97 [7846117.001]
  • [Cites] Artif Organs. 1994 Jan;18(1):1-3 [8141649.001]
  • [Cites] Mol Biol Cell. 1993 Sep;4(9):953-61 [8257797.001]
  • [Cites] Biotechnol Bioeng. 2001 Jun 5;73(5):379-89 [11320508.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Apr;301(1):382-90 [11907196.001]
  • [Cites] Clin Chem. 1962 Apr;8:130-2 [13878063.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21715-7 [7665589.001]
  • [Cites] Dig Dis Sci. 1994 Apr;39(4):851-60 [7512018.001]
  • [Cites] Biotechnol Bioeng. 1992 Oct 20;40(8):934-46 [18601201.001]
  • [Cites] Artif Organs. 1995 Sep;19(9):941-50 [8687303.001]
  • [Cites] Biotechnol Bioeng. 1999 Aug 5;64(3):357-67 [10397873.001]
  • [Cites] Biotechnol Bioeng. 1999 Aug 20;64(4):401-17 [10397879.001]
  • [Cites] Biomaterials. 2000 Apr;21(8):783-93 [10721747.001]
  • [Cites] Drug Metab Dispos. 2001 Feb;29(2):121-6 [11159800.001]
  • [Cites] Pharmacol Ther. 1991;51(3):347-69 [1792239.001]
  • [Cites] Biotechnol Bioeng. 1994 Jun 20;44(2):184-93 [18618684.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Apr 15;184(1):225-30 [1567430.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1179-86 [1699862.001]
  • [Cites] J Chromatogr. 1991 Sep 18;570(1):77-88 [1797838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1643-7 [287004.001]
  • [Cites] Eur J Biochem. 1977 Jun 1;76(1):7-12 [880950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251-5 [2444978.001]
  • [Cites] J Cell Biol. 1994 Oct;127(2):537-46 [7523422.001]
  • [Cites] Science. 1995 Feb 10;267(5199):891-3 [7531366.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Science. 1996 Jan 26;271(5248):499-502 [8560263.001]
  • [Cites] J Cell Biol. 1996 Apr;133(2):391-403 [8609171.001]
  • [Cites] Biotechnol Bioeng. 1998 Mar 5;57(5):518-28 [10099230.001]
  • [Cites] Cytotechnology. 1998 Jan;26(1):5-12 [22359001.001]
  • [Cites] Biotechnol Prog. 1991 May-Jun;7(3):237-45 [1367596.001]
  • [Cites] Gastroenterology. 1990 Jan;98(1):197-202 [2293578.001]
  • [Cites] Semin Liver Dis. 1990 Feb;10(1):11-9 [2336565.001]
  • [Cites] Eur J Biochem. 1988 Apr 15;173(2):287-93 [2452086.001]
  • [Cites] Drug Metab Dispos. 1988 Jul-Aug;16(4):605-8 [2903030.001]
  • [Cites] FASEB J. 1989 Feb;3(2):174-7 [2914628.001]
  • [Cites] Arch Biochem Biophys. 1986 Nov 1;250(2):469-75 [3096213.001]
  • [Cites] Hepatology. 1988 Mar-Apr;8(2):385-401 [3281888.001]
  • [Cites] Ann Surg. 1986 Sep;204(3):259-71 [3530153.001]
  • [Cites] J Cell Biol. 1972 Sep;54(3):626-37 [4339818.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1379-92 [9210627.001]
  • [Cites] Glycobiology. 1999 Feb;9(2):125-31 [9949190.001]
  • [Cites] Biotechnol Prog. 2000 Jan-Feb;16(1):102-8 [10662497.001]
  • [Cites] Exp Mol Med. 2000 Mar 31;32(1):29-37 [10762059.001]
  • [Cites] Biochem J. 1984 Dec 1;224(2):505-14 [6083778.001]
  • (PMID = 19002882.001).
  • [ISSN] 0920-9069
  • [Journal-full-title] Cytotechnology
  • [ISO-abbreviation] Cytotechnology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3449807
  •  go-up   go-down


33. Mirsky R, Woodhoo A, Parkinson DB, Arthur-Farraj P, Bhaskaran A, Jessen KR: Novel signals controlling embryonic Schwann cell development, myelination and dedifferentiation. J Peripher Nerv Syst; 2008 Jun;13(2):122-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel signals controlling embryonic Schwann cell development, myelination and dedifferentiation.
  • When axons degenerate following injury, Schwann cells demyelinate, proliferate and dedifferentiate to assume a molecular phenotype similar to that of immature cells, a process essential for successful nerve regeneration.
  • Increasing evidence indicates that Schwann cell dedifferentiation involves activation of specific receptors, intracellular signalling pathways and transcription factors in a manner analogous to myelination.
  • Notch is elevated in injured nerves where it accelerates the rate of dedifferentiation.
  • Forced expression of c-Jun in Schwann cells prevents myelination, and in injured nerves, c-Jun is required for appropriate dedifferentiation, the re-emergence of the immature Schwann cell state and nerve regeneration.
  • The growing realisation that myelination is subject to negative as well as positive controls and progress in molecular identification of negative regulators is likely to impact on our understanding of demyelinating disease and mechanisms that control nerve repair.
  • [MeSH-major] Cell Dedifferentiation / physiology. Cell Differentiation / physiology. Embryonic Development / physiology. Myelin Sheath / physiology. Schwann Cells / physiology. Signal Transduction / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18601657.001).
  • [ISSN] 1529-8027
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601943; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


34. Okada K, Hasegawa T, Tateishi U, Endo M, Itoi E: Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features. J Clin Pathol; 2006 Nov;59(11):1200-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features.
  • Radiographs showed a poorly demarcated osteolytic lesion with focal mineralisation and endosteal scalloping in the left proximal femur.
  • Biopsy showed a proliferation of highly anaplastic cells without any cartilaginous component.
  • The patient was diagnosed with dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features.
  • Establishing a definitive diagnosis of dedifferentiated chondrosarcoma may be difficult with limited small biopsy specimens.
  • Dedifferentiated chondrosarcoma should be included in the differential diagnosis of osteolytic tumours with focal calcification and endosteal scalloping even if an extraosseous tumour component is not identified.
  • [MeSH-minor] Adult. Cell Differentiation. Femur. Humans. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1999 Nov;31(4):428-30 [10643020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):55-61 [10697315.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):159-63 [12089726.001]
  • [Cites] Cancer. 1971 Aug;28(2):461-6 [5566365.001]
  • [Cites] J Bone Joint Surg Am. 1986 Oct;68(8):1197-205 [3021775.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):293-8 [8772782.001]
  • [Cites] Cancer. 1976 Dec;38(6):2538-47 [1069603.001]
  • (PMID = 17071806.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860503
  •  go-up   go-down


35. Tejerina S, De Pauw A, Vankoningsloo S, Houbion A, Renard P, De Longueville F, Raes M, Arnould T: Mild mitochondrial uncoupling induces 3T3-L1 adipocyte de-differentiation by a PPARgamma-independent mechanism, whereas TNFalpha-induced de-differentiation is PPARgamma dependent. J Cell Sci; 2009 Jan 1;122(Pt 1):145-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild mitochondrial uncoupling induces 3T3-L1 adipocyte de-differentiation by a PPARgamma-independent mechanism, whereas TNFalpha-induced de-differentiation is PPARgamma dependent.
  • In this report, we characterized the 3T3-L1-adipocyte ;de-differentiation' induced by carbonyl cyanide (p-trifluoromethoxy)-phenylhydrazone (FCCP), a mitochondrial uncoupler.
  • We next analyzed the expression of genes encoding adipogenic markers and effectors and compared the differentially expressed genes in adipocytes treated with FCCP or TNFalpha (a cytokine known to induce adipocyte de-differentiation).
  • These results highlight some new mechanisms that might potentially be involved in adipocyte de-differentiation initiated by a mitochondrial uncoupling.
  • [MeSH-major] 3T3-L1 Cells / metabolism. Cell Dedifferentiation / physiology. Mitochondria. PPAR gamma / metabolism. Tumor Necrosis Factor-alpha / metabolism. Uncoupling Agents / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066287.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / PPAR gamma; 0 / Retinoid X Receptors; 0 / Tumor Necrosis Factor-alpha; 0 / Uncoupling Agents; 370-86-5 / Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone
  •  go-up   go-down


36. Baumer Y, Funk D, Schlosshauer B: Does telomerase reverse transcriptase induce functional de-differentiation of human endothelial cells? Cell Mol Life Sci; 2010 Jul;67(14):2451-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does telomerase reverse transcriptase induce functional de-differentiation of human endothelial cells?
  • Embryonic cells display a high telomerase activity that declines rapidly with cell differentiation.
  • Conversely, de-differentiated tumor cells tend to re-express telomerase.
  • In view of the controversial data on the reciprocal correlation between cell proliferation and differentiation, we questioned whether telomerase overexpression and the resulting immortalization would affect the functional phenotype of human endothelial cells.
  • Our results, based on some 40 data sets, demonstrate that immortalization of primary endothelial cells by hTERT maintains the typical endothelial characteristics without any sign of functional de-differentiation.
  • [MeSH-major] Cell Dedifferentiation. Endothelial Cells / cytology. Endothelial Cells / physiology. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Aug 22;90(4):785-95 [9288757.001]
  • [Cites] Microvasc Res. 2002 Nov;64(3):384-97 [12453433.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Dec;31(11):846-52 [8826088.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H92-H100 [12388327.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26141-8 [10473565.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1154-68 [18644980.001]
  • [Cites] J Cell Sci. 1993 Apr;104 ( Pt 4):1073-81 [8314892.001]
  • [Cites] Cardiovasc Res. 2008 May 1;78(2):265-73 [18281374.001]
  • [Cites] Int Immunopharmacol. 2009 Feb;9(2):258 [19015046.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8079-84 [11719431.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Apr 25;221(3):697-702 [8630024.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):115-8 [9916803.001]
  • [Cites] Microcirculation. 1999 Mar;6(1):45-54 [10100188.001]
  • [Cites] Circulation. 2008 Dec 9;118(24):2563-70 [19029464.001]
  • [Cites] Crit Care Med. 2009 May;37(5):1735-43 [19325485.001]
  • [Cites] Differentiation. 2010 Jan;79(1):1-8 [19811869.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Bioessays. 2004 Sep;26(9):955-62 [15351966.001]
  • [Cites] Eur J Cell Biol. 2009 May;88(5):285-300 [19246119.001]
  • [Cites] Lab Invest. 2001 Dec;81(12):1717-27 [11742042.001]
  • [Cites] Cell Cycle. 2004 Jun;3(6):811-6 [15118409.001]
  • [Cites] FASEB J. 1995 Jul;9(10):910-8 [7615160.001]
  • [Cites] Microvasc Res. 1987 Sep;34(2):239-49 [2823081.001]
  • [Cites] J Cell Biol. 1992 Sep;118(6):1511-22 [1522121.001]
  • [Cites] Acta Pharmacol Sin. 2007 Jan;28(1):66-72 [17184584.001]
  • [Cites] Cytotechnology. 2001 Jul;36(1-3):137-44 [19003324.001]
  • [Cites] J Appl Physiol (1985). 2001 Oct;91(4):1487-500 [11568129.001]
  • [Cites] Cell. 1989 Sep 8;58(5):933-43 [2528412.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jul;6(7):631-6 [15973764.001]
  • [Cites] J Biomater Sci Polym Ed. 2000;11(11):1275-84 [11263813.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):625-31 [18292940.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4512-9 [12586632.001]
  • [Cites] Acta Pharmacol Sin. 2008 Jul;29(7):877-80 [18565286.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Br Heart J. 1995 Dec;74(6):580-3 [8541159.001]
  • [Cites] Nucleic Acids Res. 2009 May;37(8):2618-29 [19270068.001]
  • [Cites] Physiol Rev. 1999 Jul;79(3):703-61 [10390517.001]
  • [Cites] J Cell Biochem. 2006 May 15;98(2):267-86 [16408275.001]
  • [Cites] Biomacromolecules. 2008 Nov;9(11):2969-79 [18831592.001]
  • [Cites] J Cell Physiol. 2002 Mar;190(3):332-44 [11857449.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Anat Embryol (Berl). 1996 Nov;194(5):445-56 [8905012.001]
  • [Cites] Biotechniques. 2006 Apr;40(4):523-31 [16629399.001]
  • [Cites] Blood Coagul Fibrinolysis. 2000 Jan;11(1):15-25 [10691096.001]
  • [Cites] J Invest Dermatol. 1989 Aug;93(2 Suppl):59S-61S [2754280.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jan;294(1):C178-88 [17989211.001]
  • [Cites] J Cell Biol. 1984 Dec;99(6):2034-40 [6501412.001]
  • [Cites] FASEB J. 1990 Aug;4(11):2868-80 [2199285.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):111-4 [9916802.001]
  • [Cites] Physiol Rev. 2006 Jan;86(1):279-367 [16371600.001]
  • [Cites] Microvasc Res. 2000 Mar;59(2):265-77 [10684732.001]
  • [Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1593-8 [9815848.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):247-56 [10436167.001]
  • [Cites] Angiogenesis. 2001;4(2):91-102 [11806248.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Mar;26(3 Pt 1):265-74 [1690702.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):1095-8 [10891377.001]
  • [Cites] Cytokine Growth Factor Rev. 1996 Oct;7(3):259-70 [8971481.001]
  • [Cites] Handb Exp Pharmacol. 2006;(176 Pt 2):285-306 [16999230.001]
  • [Cites] Microvasc Res. 2001 Nov;62(3):252-62 [11678628.001]
  • [Cites] Biotechnol Prog. 2009 Jul-Aug;25(4):1130-7 [19455648.001]
  • [Cites] Pharmacol Res. 2000 Jul;42(1):9-19 [10860629.001]
  • [Cites] J Neurosci Methods. 2009 Jan 30;176(2):112-20 [18822316.001]
  • (PMID = 20352467.001).
  • [ISSN] 1420-9071
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Carbocyanines; 0 / Cell Adhesion Molecules; 0 / Lipoproteins, LDL; 0 / Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 0 / von Willebrand Factor; 126547-89-5 / Intercellular Adhesion Molecule-1; 40957-95-7 / 3,3'-dioctadecylindocarbocyanine; 82115-62-6 / Interferon-gamma; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


37. Zámecník M, Staník M: Dedifferentiated mixed stromal-smooth muscle tumor of the uterus. Report of a case. Cesk Patol; 2006 Apr;42(2):81-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated mixed stromal-smooth muscle tumor of the uterus. Report of a case.
  • So-called dedifferentiation in mesenchymal neoplasms of the uterus is very rare.
  • Among conventional low-grade stromal tumors only three cases of dedifferentiation were reported, whereas in mixed stromal-smooth muscle tumors the dedifferentiation was yet not described.
  • Here we present such a case of low-grade mixed stromal-smooth muscle tumor with dedifferentiation.
  • The high-grade component representing a dedifferentiation showed morphology of undifferentiated sarcoma with myxoid change.
  • The low-grade component with morphology of mixed stromal-smooth muscle tumor was limited to a few peripheral areas of the lesion.
  • Immunohistochemically, the low-grade component showed typical positivity for CD10, estrogen receptor, progesterone receptor, and focal reactivity for myoid markers, whereas the dedifferentiated component expressed only vimentin, CD10 and estrogen receptor.
  • This case demonstrates that low-grade mixed stromal-smooth muscle tumor of the uterus can dedifferentiate like a pure stromal tumor.
  • It shows that extensive sampling/histological search may be needed for recognition of a minor component in a dedifferentiated tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cesk Patol. 2006 Jul;42(3):149
  • (PMID = 16715633.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


38. Kenan S, Ginat DT, Steiner GC: Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol; 2007 Apr;36(4):347-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula.
  • However, it has the potential to recur, dedifferentiate, and metastasize subsequent to surgical treatment.
  • In extremely rare occasions, LGCOS presents with areas of dedifferentiation upon initial patient evaluation.
  • Microscopically, the lesion consisted of high-grade osteosarcoma as well as an underlying LGCOS that involved the cortex and medullary cavity of the fibula.
  • This is the third documented case of dedifferentiated LGCOS at initial presentation.


39. Weinberg N, Ouziel-Yahalom L, Knoller S, Efrat S, Dor Y: Lineage tracing evidence for in vitro dedifferentiation but rare proliferation of mouse pancreatic beta-cells. Diabetes; 2007 May;56(5):1299-304
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage tracing evidence for in vitro dedifferentiation but rare proliferation of mouse pancreatic beta-cells.
  • Recent studies have raised the possibility that human beta-cells can undergo dedifferentiation and give rise to highly proliferative mesenchymal cells, which retain the potential to redifferentiate into beta-cells.
  • To directly test whether cultured beta-cells dedifferentiate, we applied genetic lineage tracing in mice.
  • Differentiated beta-cells were heritably labeled using the Cre-lox system, and their fate in culture was followed.
  • We provide evidence that mouse beta-cells can undergo dedifferentiation in vitro into an insulin-, pdx1-, and glut2-negative state.
  • However, dedifferentiated beta-cells only rarely proliferate under standard culture conditions and are eventually eliminated from cultures.
  • [MeSH-major] Cell Differentiation / physiology. Cell Division / physiology. Insulin-Secreting Cells / cytology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303800.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Insulin; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


40. Satoh A, Bryant SV, Gardiner DM: Regulation of dermal fibroblast dedifferentiation and redifferentiation during wound healing and limb regeneration in the Axolotl. Dev Growth Differ; 2008 Dec;50(9):743-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of dermal fibroblast dedifferentiation and redifferentiation during wound healing and limb regeneration in the Axolotl.
  • AmTwist is expressed during the blastema stages in regeneration, but is inhibited by signals from the nerve during the early stages when dermal fibroblasts dedifferentiate to form blastema cells.
  • The nerve appears to have a dual function in regeneration by coordinately regulating dedifferentiation and redifferentiation of dermal fibroblasts.
  • [MeSH-minor] Amphibian Proteins / genetics. Amphibian Proteins / metabolism. Animals. Cell Dedifferentiation. Cell Differentiation. Dermis / cytology. Twist Transcription Factor / genetics. Twist Transcription Factor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046162.001).
  • [ISSN] 1440-169X
  • [Journal-full-title] Development, growth & differentiation
  • [ISO-abbreviation] Dev. Growth Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amphibian Proteins; 0 / Twist Transcription Factor
  •  go-up   go-down


41. Zhang C, Fu X, Chen P, Bao X, Li F, Sun X, Lei Y, Cai S, Sun T, Sheng Z: Dedifferentiation derived cells exhibit phenotypic and functional characteristics of epidermal stem cells. J Cell Mol Med; 2010 May;14(5):1135-45
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiation derived cells exhibit phenotypic and functional characteristics of epidermal stem cells.
  • Differentiated epidermal cells can dedifferentiate into stem cells or stem cell-like cells in vivo.
  • In this study, we report the isolation and characterization of dedifferentiation-derived cells.
  • Then we isolated these cells on the basis of rapid adhesion to type IV collagen and found that there were 4.56% adhering cells (dedifferentiation-derived cells) in the grafting group within 10 min.
  • The in vitro phenotypic assays showed that the expressions of CK19, beta1-integrin, Oct4 and Nanog in dedifferentiation-derived cells were remarkably higher than those in the control group (differentiated epidermal cells) (P < 0.01).
  • In addition, the results of the functional investigation of dedifferentiation-derived cells demonstrated:.
  • (2) more cells were in S phase and G2/M phase of the cell cycle (proliferation index values were 21.02% in control group, 45.08% in group of dedifferentiation);.
  • (3) the total days of culture (28 days versus 130 days), the passage number of cells (3 passages versus 20 passages) and assumptive total cell output (1 x 10(5) cells versus 1 x 10(12) cells) were all significantly increased and (4) dedifferentiation-derived cells, as well as epidermal stem cells, were capable of regenerating a skin equivalent, but differentiated epidermal cells could not.
  • These results suggested that the characteristics of dedifferentiation-derived cells cultured in vitro were similar to epidermal stem cells.
  • [MeSH-major] Cell Dedifferentiation. Epidermis / cytology. Stem Cells / cytology. Stem Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19426155.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Biomarkers; 0 / Homeodomain Proteins; 0 / Keratin-19; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  • [Other-IDs] NLM/ PMC3822750
  •  go-up   go-down


42. Liao Y, Gao J, Lu F: [Comparative study on potential of adipogenic differentiation between dedifferentiated adipocytes and adipose-derived stromal cells]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2010 Jun;24(6):749-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study on potential of adipogenic differentiation between dedifferentiated adipocytes and adipose-derived stromal cells].
  • To study the seed cells with high potential of adipogenic differentiation for applying the adipose tissue engineering and increasing the constructing efficiency of adipose tissue engineering.
  • MA were cultured and induced to dedifferentiated adipocytes (DA) by ceiling adherent culture method.
  • DA and ADSCs were induced to adipogenic differentiation.
  • RESULTS: MA could dedifferentiate into fibroblast-shaped DA.
  • After adipogenic differentiation, the inverted phase contrast microscope observation showed that there were much more lipid droplet in DA than in ADSCs.
  • However, the same phenomenon could be observed in ADSCs at 10 days after differentiation.
  • CONCLUSION: The potential of adipogenic differentiation of DA is stronger than that of ADSCs.
  • [MeSH-major] Adipocytes / cytology. Cell Differentiation. Stromal Cells / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20632515.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


43. Monje PV, Soto J, Bacallao K, Wood PM: Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: role of cAMP and JNK in the maintenance of the differentiated state. J Biol Chem; 2010 Oct 1;285(40):31024-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: role of cAMP and JNK in the maintenance of the differentiated state.
  • Myelinating Schwann cells (SCs) are highly plastic cells that are able to dedifferentiate and re-enter the cell cycle.
  • However, the molecular signals controlling dedifferentiation are not completely understood.
  • Because a connection between mitogenic signaling and myelin loss has been suggested, we investigated the role of cAMP, a strong inducer of the myelinating phenotype, and mitogenic factors activating receptor tyrosine kinases (RTKs) on SC dedifferentiation.
  • We herein provide evidence indicating that cAMP was required to not only initiate but also maintain a state of differentiation because SCs rapidly dedifferentiated and became competent to resume proliferation upon the removal of cAMP stimulation.
  • Surprisingly, isolated SCs could undergo multiple cycles of differentiation and dedifferentiation upon cAMP addition and removal, respectively, in the absence of mitogenic factors and without entering the cell cycle.
  • Conversely, the activation of RTKs and the ERK cascade by a variety of growth factors, including neuregulin, was not sufficient to initiate dedifferentiation in the presence of cAMP.
  • Importantly, a reduction of cAMP triggered dedifferentiation through a mechanism that required JNK, rather than ERK, activity and an induction of the expression of c-Jun, a transcriptional inhibitor of myelination.
  • In summary, the reversible transition from an undifferentiated to a myelinating state was dependent on cAMP but independent of RTK signaling and cell cycle progression, further indicating that dedifferentiation and proliferation are uncoupled and differentially regulated events in SCs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1994 Oct 27;371(6500):796-9 [7935840.001]
  • [Cites] Ann N Y Acad Sci. 1991;633:78-89 [1665043.001]
  • [Cites] J Neurochem. 1995 Jul;65(1):149-59 [7540661.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20805-10 [8702835.001]
  • [Cites] J Mol Med (Berl). 1996 Oct;74(10):589-607 [8912180.001]
  • [Cites] Acta Stomatol Belg. 1996 Mar;93(1):29-32 [8986050.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18623-32 [9660836.001]
  • [Cites] Cloning Stem Cells. 2004;6(4):333-44 [15671661.001]
  • [Cites] J Neurosci. 2005 Mar 30;25(13):3478-87 [15800203.001]
  • [Cites] Glia. 2006 Apr 15;53(6):649-59 [16470843.001]
  • [Cites] Nat Med. 2006 Aug;12(8):961-6 [16892039.001]
  • [Cites] Artif Organs. 2006 Oct;30(10):743-55 [17026573.001]
  • [Cites] Annu Rev Neurosci. 2007;30:209-33 [17341159.001]
  • [Cites] J Neurosci. 2008 Apr 2;28(14):3738-46 [18385332.001]
  • [Cites] Mol Cell Neurosci. 2008 May;38(1):80-8 [18374600.001]
  • [Cites] J Cell Biol. 2008 May 19;181(4):625-37 [18490512.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1552-65 [18803323.001]
  • [Cites] J Biol Chem. 2008 Dec 5;283(49):34087-100 [18799465.001]
  • [Cites] Neurosci Lett. 2009 Jun 12;456(3):124-32 [19429147.001]
  • [Cites] Glia. 2009 Jul;57(9):947-61 [19053056.001]
  • [Cites] Nat Neurosci. 2009 Jul;12(7):839-47 [19525946.001]
  • [Cites] Science. 2009 Sep 11;325(5946):1402-5 [19745155.001]
  • [Cites] J Neurosci. 2010 Apr 28;30(17):6122-31 [20427670.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 9;266(1):129-34 [10581177.001]
  • [Cites] Neuron. 2000 May;26(2):405-16 [10839359.001]
  • [Cites] J Neurosci. 2000 Jun 15;20(12):4635-45 [10844033.001]
  • [Cites] Bioessays. 2000 Sep;22(9):818-26 [10944584.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1110-6 [11160381.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1289-99 [11257128.001]
  • [Cites] Differentiation. 2000 Dec;66(4-5):239-46 [11269950.001]
  • [Cites] J Anat. 2001 Jul-Aug;199(Pt 1-2):3-11 [11523827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6 [11717429.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):566-74 [12154368.001]
  • [Cites] J Surg Oncol. 2003 Sep;84(1):24-30 [12949987.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):7030-43 [12972619.001]
  • [Cites] J Cell Biol. 2004 Feb 2;164(3):385-94 [14757751.001]
  • [Cites] Nat Med. 2004 Jun;10(6):610-6 [15156204.001]
  • [Cites] J Neurosci. 2004 Jul 28;24(30):6724-32 [15282275.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3061-71 [15241478.001]
  • [Cites] J Anat. 1970 May;106(Pt 3):463-70 [5423939.001]
  • [Cites] Brain Res. 1979 Apr 6;165(1):105-18 [371755.001]
  • [Cites] J Cell Biol. 1980 Mar;84(3):767-78 [6153659.001]
  • [Cites] Brain Res. 1986 Jan 1;362(1):23-32 [3002553.001]
  • [Cites] EMBO J. 1988 Jun;7(6):1635-45 [3049071.001]
  • [Cites] Cell. 1988 Dec 2;55(5):875-85 [3142689.001]
  • [Cites] J Neurosci. 1991 Aug;11(8):2433-42 [1869923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1431-5 [7877996.001]
  • (PMID = 20634285.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS009923; United States / NINDS NIH HHS / NS / NS009923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuregulins; 0 / Proto-Oncogene Proteins c-jun; E0399OZS9N / Cyclic AMP; EC 2.7.12.2 / MAP Kinase Kinase 4
  • [Other-IDs] NLM/ PMC2945593
  •  go-up   go-down


44. Chen X, Mao Z, Liu S, Liu H, Wang X, Wu H, Wu Y, Zhao T, Fan W, Li Y, Yew DT, Kindler PM, Li L, He Q, Qian L, Wang X, Fan M: Dedifferentiation of adult human myoblasts induced by ciliary neurotrophic factor in vitro. Mol Biol Cell; 2005 Jul;16(7):3140-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiation of adult human myoblasts induced by ciliary neurotrophic factor in vitro.
  • Surprisingly, we found that CNTF induced the myogenic lineage-committed myoblasts at a clonal level to dedifferentiate into multipotent progenitor cells--they not only could proliferate for over 20 passages with the expression absence of myogenic specific factors Myf5 and MyoD, but they were also capable of differentiating into new phenotypes, mainly neurons, glial cells, smooth muscle cells, and adipocytes.
  • Our results demonstrate the myogenic lineage-committed human myoblasts can dedifferentiate at a clonal level and CNTF is a novel regulator of skeletal myoblast dedifferentiation via p44/p42 MAPK pathway.
  • [MeSH-minor] Animals. Biopsy. Blotting, Western. Cell Differentiation. Cell Lineage. Cell Proliferation. Cells, Cultured. Down-Regulation. Enzyme Inhibitors / pharmacology. Flavonoids / pharmacology. Humans. Immunohistochemistry. In Vitro Techniques. Male. Mice. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. MyoD Protein / metabolism. Myoblasts / metabolism. Myogenic Regulatory Factor 5 / metabolism. NIH 3T3 Cells. Neuroglia / cytology. Neurons / metabolism. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Stem Cells / cytology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2002 Feb;143(2):511-6 [11796505.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11458-63 [10500198.001]
  • [Cites] Gene Ther. 2002 May;9(10):642-7 [12032710.001]
  • [Cites] J Cell Biol. 2002 May 27;157(5):851-64 [12021255.001]
  • [Cites] Dev Cell. 2002 Jun;2(6):707-12 [12062083.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3099-108 [12202535.001]
  • [Cites] J Neurosci Res. 2002 Sep 15;69(6):894-907 [12205682.001]
  • [Cites] Semin Cell Dev Biol. 2002 Oct;13(5):353-60 [12324217.001]
  • [Cites] Mol Cell Biochem. 2002 Sep;238(1-2):27-39 [12349907.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):123-34 [12379804.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49831-40 [12244043.001]
  • [Cites] J Neurosci Res. 2003 Jan 15;71(2):228-36 [12503085.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2228-35 [12424252.001]
  • [Cites] J Biol Chem. 2003 May 2;278(18):15897-904 [12609984.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Aug;35(8):1151-6 [12757751.001]
  • [Cites] Nat Rev Genet. 2003 Jul;4(7):497-507 [12838342.001]
  • [Cites] Exp Cell Res. 2003 Nov 15;291(1):83-90 [14597410.001]
  • [Cites] J Neurosci Res. 2003 Nov 15;74(4):533-40 [14598297.001]
  • [Cites] Mol Vis. 2003 Dec 16;9:715-22 [14685141.001]
  • [Cites] J Am Chem Soc. 2004 Jan 21;126(2):410-1 [14719906.001]
  • [Cites] Development. 2004 Feb;131(4):713-23 [14724123.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):254-68 [14980519.001]
  • [Cites] Nat Neurosci. 2004 Mar;7(3):229-35 [14770186.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • [Cites] Acta Physiol Scand. 2004 Apr;180(4):395-403 [15030381.001]
  • [Cites] Science. 1979 Jun 29;204(4400):1434-6 [451576.001]
  • [Cites] Science. 1989 Mar 17;243(4897):1450-5 [2648568.001]
  • [Cites] Science. 1991 Mar 29;251(5001):1616-8 [2011743.001]
  • [Cites] J Cell Biol. 1991 Oct;115(2):447-59 [1918150.001]
  • [Cites] Nature. 1993 Aug 5;364(6437):501-6 [8393145.001]
  • [Cites] Cell. 1994 Feb 11;76(3):493-504 [8313470.001]
  • [Cites] J Biol Chem. 1994 Apr 15;269(15):11648-55 [7512571.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1275-87 [8207057.001]
  • [Cites] Transgenic Res. 1994 May;3(3):152-8 [8025594.001]
  • [Cites] Development. 1995 Oct;121(10):3347-58 [7588068.001]
  • [Cites] Development. 1997 Mar;124(5):1055-67 [9056780.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 12;1402(1):39-51 [9551084.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10436-44 [9553102.001]
  • [Cites] J Neurosci. 1998 May 15;18(10):3620-9 [9570793.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Sep;57(9):850-7 [9737548.001]
  • [Cites] J Neurosci. 1999 Feb 15;19(4):1257-62 [9952403.001]
  • [Cites] Dev Biol. 1999 Feb 15;206(2):219-31 [9986734.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):132-8 [10448081.001]
  • [Cites] Biol Chem. 1999 Jul-Aug;380(7-8):803-13 [10494829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14482-6 [10588731.001]
  • [Cites] Pharm Acta Helv. 2000 Mar;74(2-3):265-72 [10812968.001]
  • [Cites] Science. 2000 Jun 2;288(5471):1660-3 [10834848.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1099-109 [11163185.001]
  • [Cites] Mol Cell Neurosci. 2001 Feb;17(2):373-84 [11178874.001]
  • [Cites] Mol Cell Neurosci. 2001 Mar;17(3):426-43 [11273640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4652-7 [11259650.001]
  • [Cites] Tissue Eng. 2001 Apr;7(2):211-28 [11304456.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):13709-17 [11279003.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):118-21 [11464862.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7642-53 [11567054.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):245-53 [11776477.001]
  • [Cites] Eur J Biochem. 2002 Feb;269(3):850-8 [11846786.001]
  • (PMID = 15843428.001).
  • [ISSN] 1059-1524
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Ciliary Neurotrophic Factor; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / MYF5 protein, human; 0 / MyoD Protein; 0 / Myogenic Regulatory Factor 5; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ PMC1165399
  •  go-up   go-down


45. Aitken KJ, Tolg C, Panchal T, Leslie B, Yu J, Elkelini M, Sabha N, Tse DJ, Lorenzo AJ, Hassouna M, Bägli DJ: Mammalian target of rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain, hypoxia, and extracellular matrix remodeling) in rat bladder smooth muscle. Am J Pathol; 2010 Jan;176(1):304-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain, hypoxia, and extracellular matrix remodeling) in rat bladder smooth muscle.
  • Maladaptive bladder muscle overgrowth and de-differentiation in human bladder obstructive conditions is instigated by coordinate responses to three stimuli: mechanical strain, tissue hypoxia, and extracellular matrix remodeling.( 1,2) Pathway analysis of genes induced by obstructive models of injury in bladder smooth muscle cells (BSMCs) identified a mammalian target of rapamycin (mTOR)-specific inhibitor as a potential pharmacological inhibitor.
  • Rapamycin also supported smooth muscle actin expression in response to strain or hypoxia-induced de-differentiation.
  • These results point to a coordinate role for mTOR in BSMCs responses to the three stimuli and a potential new therapeutic target for myopathic bladder disease.
  • [MeSH-major] Cell Dedifferentiation. Extracellular Matrix / pathology. Intracellular Signaling Peptides and Proteins / metabolism. Myocytes, Smooth Muscle / enzymology. Myocytes, Smooth Muscle / pathology. Protein-Serine-Threonine Kinases / metabolism. Stress, Mechanical. Urinary Bladder / pathology

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 Jun;85(9):1109-14 [10848706.001]
  • [Cites] BJU Int. 2007 Apr;99(4):831-5 [17244278.001]
  • [Cites] J Urol. 2001 Jun;165(6 Pt 2):2235-40 [11371952.001]
  • [Cites] J Urol. 2002 Mar;167(3):1508-12 [11832779.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2799-809 [11909972.001]
  • [Cites] Lab Invest. 2002 Jul;82(7):903-9 [12118092.001]
  • [Cites] J Urol. 2003 Feb;169(2):750-5 [12544357.001]
  • [Cites] J Urol. 2003 Jun;169(6):2388-93 [12771803.001]
  • [Cites] Am J Health Syst Pharm. 2003 Jun 15;60(12):1210, 1212 [12845914.001]
  • [Cites] J Urol. 2003 Nov;170(5):2072-6 [14532856.001]
  • [Cites] J Urol. 2003 Nov;170(5):2077-81 [14532857.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1754-60 [12958040.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8862-77 [14612424.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):200-16 [14673156.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Mar;286(3):C507-17 [14592809.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Apr;286(4):R642-8 [14656765.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Physiol Rev. 2004 Jul;84(3):767-801 [15269336.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Oct;287(4):F682-9 [15161603.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1524-8 [15371884.001]
  • [Cites] J Urol. 1982 Dec;128(6):1340-2 [7154206.001]
  • [Cites] Prog Clin Biol Res. 1987;249:251-62 [3671428.001]
  • [Cites] Transplant Proc. 1993 Feb;25(1 Pt 1):770-1 [7679842.001]
  • [Cites] Circ Res. 1993 Jul;73(1):109-17 [8389675.001]
  • [Cites] Eur Urol. 1997;32 Suppl 1:32-9 [9218941.001]
  • [Cites] J Cell Biol. 1997 Oct 6;139(1):279-93 [9314546.001]
  • [Cites] Pediatr Surg Int. 1998 Sep;13(7):504-7 [9716680.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):435-45 [9914156.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jan;31(1):43-57 [10216943.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4302-10 [10330171.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):C294-301 [10444406.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):832-40 [10458391.001]
  • [Cites] J Cell Biol. 2004 Nov 8;167(3):399-403 [15533996.001]
  • [Cites] Physiol Genomics. 2004 Dec 15;20(1):36-44 [15467014.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2861-8 [15708965.001]
  • [Cites] J Vasc Res. 2005 May-Jun;42(3):190-201 [15832055.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25854-63 [15886193.001]
  • [Cites] Circulation. 2005 Jul 19;112(3):423-31 [16027270.001]
  • [Cites] Int Braz J Urol. 2005 Nov-Dec;31(6):579-85; discussion 586 [16386129.001]
  • [Cites] Nephron Exp Nephrol. 2006;102(1):e1-7 [16179802.001]
  • [Cites] Early Hum Dev. 2006 Jan;82(1):15-22 [16377104.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6760-7 [17638887.001]
  • [Cites] Ann Vasc Surg. 2007 Nov;21(6):734-41 [17923382.001]
  • [Cites] FEBS Lett. 2007 Dec 22;581(30):5847-51 [18053813.001]
  • [Cites] Growth Factors. 2007 Aug;25(4):209-26 [18092230.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 May;28(5):820-6 [18292395.001]
  • [Cites] Catheter Cardiovasc Interv. 2008 Oct 1;72(4):459-67 [18814274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):19006-11 [19020099.001]
  • [Cites] BJU Int. 2009 Feb;103(4):537-40 [18990141.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G755-63 [19221016.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 May-Jun;42(5-6):124-33 [16848631.001]
  • [Cites] Cell Tissue Res. 2006 Oct;326(1):149-58 [16705451.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):459-70 [16877348.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] J Urol. 2006 Sep;176(3):1225-9 [16890730.001]
  • [Cites] Nephrol Dial Transplant. 2006 Oct;21 Suppl 5:v13-6 [16959789.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1293-302 [17043666.001]
  • [Cites] Acta Med Okayama. 2006 Dec;60(6):299-309 [17189973.001]
  • [Cites] BJU Int. 2007 Feb;99(2):418-30 [17313427.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Oct;279(4):C1155-67 [11003596.001]
  • (PMID = 20019183.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitogens; 0 / smooth muscle actin, rat; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, rat; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; EC 2.7.11.1 / S6K1 protein, rat; EC 3.4.24.23 / Matrix Metalloproteinase 7; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2797892
  •  go-up   go-down


46. Dominguez E, Lopez de Cenarruzabeitia I, Martinez M, Rueda JC, Lede A, Barreiro E, Diz S: Giant dedifferentiated retroperitoneal liposarcoma. Int Surg; 2008 Jul-Aug;93(4):247-9
Genetic Alliance. consumer health - Retroperitoneal liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant dedifferentiated retroperitoneal liposarcoma.
  • It has a great tendency for local recurrence, mainly the dedifferentiated variety, but its complete resection can provide a 5-year survival of 70%.
  • In this report, we present a case of a giant dedifferentiated retroperitoneal liposarcoma that did not affect any neighboring organ and that was successfully treated by means of complete surgical resection.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19731863.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


47. Coindre JM, Pédeutour F, Aurias A: Well-differentiated and dedifferentiated liposarcomas. Virchows Arch; 2010 Feb;456(2):167-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated and dedifferentiated liposarcomas.
  • Atypical lipomatous tumor or well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) share the same basic genetic abnormality characterized by a simple genomic profile with a 12q14-15 amplification involving MDM2 gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10 ):1557-66 [17895758.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Nov;155(1):1-24 [15527898.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 [11960696.001]
  • [Cites] Cell Biol Int. 2007 Jun;31(6):586-91 [17240171.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):945-55 [9706974.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10 ):1476-89 [17895748.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1657-65 [18704991.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] Histopathology. 2007 Sep;51(3):422-6 [17727490.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1770-83 [16603719.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):256-62 [12640106.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):15-29 [10721693.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10 ):1340-7 [16160477.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):546-56 [8333554.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10 ):2233-41 [18214854.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4673-80 [15122339.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):32-7 [15034865.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Oct;29(2):117-29 [10959091.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):361-74 [17418412.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):24-9 [12547153.001]
  • [Cites] Cancer Lett. 2009 Jan 18;273(2):323-30 [18823700.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Bull Cancer. 2004 Apr;91(4):317-23 [15242313.001]
  • [Cites] Cancer. 1979 Feb;43(2):574-84 [421182.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):407-16 [16415793.001]
  • [Cites] Histopathology. 1998 Nov;33(5):414-24 [9839165.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):176-81 [15702084.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):199-205 [17354236.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jun;10(2):85-94 [7520271.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Histopathology. 1997 Jun;30(6):507-11 [9205853.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14 ):6626-36 [17638873.001]
  • [Cites] Am J Surg Pathol. 1987 Mar;11(3):161-83 [3826477.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):518-27 [9158675.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):381-91 [16926564.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1051-8 [1471725.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):943-9 [18500263.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1271-5 [10755400.001]
  • [Cites] J Pathol. 2004 Jul;203(3):822-30 [15221942.001]
  • (PMID = 19688222.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Number-of-references] 46
  •  go-up   go-down


48. Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Müller A, Tuschl G, Mueller SO, Dooley S: Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology; 2009 Jun;49(6):2031-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis.
  • However, it is well established that hepatocytes cultured on monolayers of dried stiff collagen dedifferentiate, losing specialized liver functions.
  • In this study, we show that hepatocyte dedifferentiation is a reversible consequence of a specific signaling network constellation triggered by the extracellular matrix.
  • Our results demonstrate that hepatocyte dedifferentiation in vitro is an active process driven by FAK-mediated Akt and ERK1/2 signaling.
  • CONCLUSION: Hepatocytes can exist in a differentiated and a dedifferentiated state that are reversible and can be switched by manipulating the responsible key factors of the signaling network.
  • [MeSH-major] Apoptosis. Cell Dedifferentiation. Extracellular Matrix / physiology. Hepatocytes / cytology. Hepatocytes / physiology. Transforming Growth Factor beta / physiology


49. Jabari S, Meissnitzer M, Quint K, Gahr S, Wissniowski T, Hahn EG, Neureiter D, Ocker M: Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo. Int J Oncol; 2009 Jul;35(1):69-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo.
  • Tumor cells have the capability to trans- and to dedifferentiate, for example by reactivating embryonic development genes and stem cell characteristics.
  • Specimens were characterized by quantitative real-time PCR, Western blotting, methylation-specific PCR and immunohistochemistry for markers of differentiation (cytokeratins, vimentin), embryonic development or stem cells (PTC, PDX-1, SHH, Thy1, c-kit, CD34, beta-catenin, Ki-67).
  • The investigated HCC cell lines showed different patterns of marker expression allowing to distinguish four distinct groups: the classical cholangiocellular type (Huh-7, Huh-7 pcDNA3.1, Hep3B) with expression of CK7/19, beta-catenin and CD34; a dedifferentiated mesenchymal-proliferative type (Huh-7 5-15) characterized by CK19, Vimentin and Ki-67; a dedifferentiated embryonic-development type (Hep3B implanted in matrigel) with expression of CK19, beta-catenin and PTC and a classical HCC type (HepG2) showing CK18/19 and beta-catenin expression.
  • HCC cell lines showed significantly different expression patterns of differentiation markers in a xenograft model.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Cell Dedifferentiation / genetics. Cell Transdifferentiation / genetics. Liver Neoplasms / genetics. Neoplastic Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513553.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


50. Thöm K, Bontikous S, Engelhardt M, Düring T, Schulte M: [Intracortical dedifferentiated chondrosarcoma]. Unfallchirurg; 2009 Jul;112(7):656-60
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracortical dedifferentiated chondrosarcoma].
  • During the staging examination of a 59-year-old patient referred to our clinic because of a squamous cell carcinoma of the oropharynx, we also found a highly malignant intracortical dedifferentiated chondrosarcoma of the distal femur shaft.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1991 Nov;181(2):409-13 [1924781.001]
  • [Cites] Skeletal Radiol. 1990;19(1):59-61 [2326658.001]
  • [Cites] J Bone Joint Surg Am. 2003 Mar;85-A(3):533-5 [12637443.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jun;(279):269-80 [1600666.001]
  • [Cites] Skeletal Radiol. 1996 Jul;25(5):455-9 [8837277.001]
  • [Cites] Unfallchirurg. 2002 Dec;105(12):1139-42 [12486582.001]
  • [Cites] Hum Pathol. 1998 May;29(5):438-46 [9596266.001]
  • [Cites] Skeletal Radiol. 1998 Oct;27(10 ):581-3 [9840397.001]
  • [Cites] J Bone Joint Surg Br. 1982;64(3):370-6 [7096408.001]
  • [Cites] J Bone Joint Surg Am. 1998 Nov;80(11):1673-8 [9840637.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2525-33 [7002283.001]
  • [Cites] Cancer. 1972 Sep;30(3):726-36 [5075357.001]
  • (PMID = 19543872.001).
  • [ISSN] 1433-044X
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Bierry G, Feydy A, Larousserie F, Pluot E, Guerini H, Campagna R, Dufau-Andreu C, Anract P, Babinet A, Dietemann JL, Chevrot A, Drapé JL: [Dedifferentiated chondrosarcoma: radiologic-pathologic correlation]. J Radiol; 2010 Mar;91(3 Pt 1):271-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiated chondrosarcoma: radiologic-pathologic correlation].
  • Dedifferentiated chondrosarcomas are highly malignant tumors characterized by conventional low-grade chondrosarcoma with abrupt transition to foci that have dedifferentiated into a higher-grade noncartilaginous more aggressive sarcoma.
  • The dedifferentiated component, an osteosarcoma or fibrosarcoma, determines the prognosis.
  • A diagnosis of dedifferentiated chondrosarcoma should be suggested by the presence of "tumoral dimorphism" with cartilaginous component and aggressive lytic component invading adjacent soft tissues.
  • [MeSH-minor] Aged. Bone Marrow / pathology. Bone Marrow / radiography. Cartilage / pathology. Cartilage / radiography. Cell Dedifferentiation. Female. Femur / pathology. Femur / radiography. Fibrosarcoma / diagnosis. Fibrosarcoma / pathology. Fibrosarcoma / radiography. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Osteolysis / diagnosis. Osteolysis / pathology. Osteolysis / radiography. Osteosarcoma / diagnosis. Osteosarcoma / pathology. Osteosarcoma / radiography. Prognosis. Tibia / pathology. Tibia / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20508557.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


52. Hallman MA, Zhuang S, Schnellmann RG: Regulation of dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor. J Pharmacol Exp Ther; 2008 May;325(2):520-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor.
  • Repair of injured renal epithelium is thought to be mediated by surviving renal proximal tubular cells (RPTC) that must dedifferentiate to allow the proliferation and migration necessary for epithelial regeneration.
  • Current models suggest that epidermal growth factor receptor (EGFR) activation is required for dedifferentiation characterized by enhanced vimentin expression, decreased N-cadherin expression, spindle morphology, and loss of apical-basal polarity after injury.
  • H2O2 induced the dedifferentiated phenotype that persisted >48 h; redifferentiation occurred spontaneously in the absence of exogenous growth factors after 72 to 120 h.
  • EGFR inhibition during dedifferentiation restored epithelial morphology and apical-basal polarity, and it decreased vimentin expression to control levels 24 h later.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270318.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES004410; United States / NIEHS NIH HHS / ES / T32 ES012878; United States / NCRR NIH HHS / RR / C06 RR015455; United States / NIEHS NIH HHS / ES / F30 ES013619
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cation Transport Proteins; 0 / Vimentin; BBX060AN9V / Hydrogen Peroxide; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / sodium-translocating ATPase
  •  go-up   go-down


53. Shimada S, Ishizawa T, Ishizawa K, Kamada K, Hirose T: Dedifferentiated liposarcoma with rhabdomyoblastic differentiation. Virchows Arch; 2005 Nov;447(5):835-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma with rhabdomyoblastic differentiation.
  • Dedifferentiated areas of dedifferentiated liposarcoma (DDL) usually show malignant fibrous histiocytoma (MFH)- or fibrosarcoma-like features and lack any histologic signs of specific differentiation.
  • However, some reports have demonstrated specific differentiation in these areas, with histologic features resembling those of rhabdomyosarcoma, leiomyosarcoma, and osteosarcoma.
  • By real-time PCR, amplification of mdm2 and cdk4 was confirmed in both well-differentiated and dedifferentiated areas with rhabdomyoblasts of all cases.
  • This study demonstrates that DDLs with rhabdomyosarcomatous areas have genetic alterations that are common to well-differentiated/dedifferentiated liposarcomas.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):607-14 [2058760.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):546-56 [8333554.001]
  • [Cites] Ann Surg. 1948 Feb;127(2):278-90 [17859076.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] Conn Med. 1991 Apr;55(4):200-2 [2070605.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1182-9 [8827023.001]
  • [Cites] J Pathol. 2000 Apr;190(5):531-6 [10727978.001]
  • [Cites] J Pathol. 2004 Jan;202(1):95-102 [14694526.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jun;10(2):85-94 [7520271.001]
  • [Cites] J Pathol. 1997 Jan;181(1):14-24 [9071998.001]
  • [Cites] J Pathol. 1997 Jan;181(1):8-13 [9071997.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(10 ):532-40 [9829856.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1271-5 [10755400.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):567-73 [11958662.001]
  • (PMID = 16012847.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


54. Staals EL, Bacchini P, Bertoni F: Dedifferentiated central chondrosarcoma. Cancer; 2006 Jun 15;106(12):2682-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated central chondrosarcoma.
  • BACKGROUND: The prognosis for patients who develop dedifferentiation of central chondrosarcoma traditionally has been poor.
  • Because not much has been reported about this rare lesion, many uncertainties remain about prognostic factors.
  • METHODS: In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma.
  • In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients).
  • CONCLUSIONS: Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Combined Modality Therapy. Drug Therapy. Female. Femur / pathology. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / radiography. Histiocytoma, Malignant Fibrous / therapy. Humans. Humerus / pathology. Male. Middle Aged. Neoplasm Metastasis. Pelvis / pathology. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16691621.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Munshi A, Atri SK, Pandey KC, Sharma MC: Dedifferentiated chondrosarcoma of the maxilla. J Cancer Res Ther; 2007 Jan-Mar;3(1):53-5
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chondrosarcoma of the maxilla.
  • The patient underwent surgery and the postoperative histopathology was suggestive of dedifferentiated chondrosarcoma.
  • [MeSH-minor] Adult. Cell Differentiation. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998723.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


56. Kim ES, Jang SH, Park HC, Jung EH, Moon GB: Dedifferentiated liposarcoma of the retroperitoneum. Cancer Res Treat; 2010 Mar;42(1):57-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma of the retroperitoneum.
  • A dedifferentiated liposarcoma of the retroperitoneum is an extremely rare tumor.
  • The histopathological diagnosis was dedifferentiated liposarcoma and the patient was free from recurrence on the computed tomography that was done 6 months after the operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2003 Sep-Oct;27(5):799-804 [14501373.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] Am J Surg. 2002 Jul;184(1):56-7 [12135721.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • (PMID = 20369054.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2848742
  • [Keywords] NOTNLM ; Dedifferentiation / Liposarcoma / Retroperitoneum
  •  go-up   go-down


57. Svajdler M, Bohus P, Rychlý B, Sulla I, Moram M: [Post-radiation dedifferentiation of meningioma into chondroblastic osteosarcoma]. Cesk Patol; 2009 Jan;45(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-radiation dedifferentiation of meningioma into chondroblastic osteosarcoma].
  • We report a case of post-radiation dedifferentiation of meningothelial meningioma into chondroblastic osteosarcoma.
  • To our knowledge, this case represents only the second reported case of post-radiation dedifferentiation of meningioma into osteosarcoma.

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402318.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] slo
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


58. Takeuchi K, Morii T, Yabe H, Morioka H, Mukai M, Toyama Y: Dedifferentiated parosteal osteosarcoma with well-differentiated metastases. Skeletal Radiol; 2006 Oct;35(10):778-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated parosteal osteosarcoma with well-differentiated metastases.
  • Metastases of dedifferentiated sarcoma usually contain a dedifferentiated component.
  • We report a rare case of dedifferentiated parosteal osteosarcoma (dd-POS) with well-differentiated multiple metastases in a 65-year-old woman with a painful firm mass on her thigh.
  • However, histological examination on the subcutaneous lesions in her lower leg, buttock and head showed low-grade conventional POS without dedifferentiated components.
  • To the best of our knowledge, this is the first report of a dd-POS with multiple metastases that do not contain any dedifferentiated components.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):181-6 [6584042.001]
  • [Cites] J Bone Joint Surg Am. 1994 Mar;76(3):366-78 [8126042.001]
  • [Cites] J Bone Joint Surg Br. 1984 May;66(3):313-21 [6586725.001]
  • [Cites] J Bone Joint Surg Am. 1984 Jan;66(1):53-9 [6581170.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2136-45 [8918422.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] J Orthop Sci. 2001;6(3):290-4 [11484126.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):397-403 [9211528.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):100-11 [11369052.001]
  • [Cites] Skeletal Radiol. 1998 Oct;27(10 ):574-7 [9840395.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):140-8 [1884533.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):558-61 [10886740.001]
  • [Cites] Radiology. 1996 Dec;201(3):837-42 [8939240.001]
  • (PMID = 16518652.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Kuhnen C, Mentzel T, Sciot R, Lehnhardt M, Homann HH, Debiec-Rychter M: Dedifferentiated liposarcoma with extensive lymphoid component. Pathol Res Pract; 2005;201(4):347-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma with extensive lymphoid component.
  • An unusual variant of dedifferentiated liposarcoma with extensive lymphocytic component is described.
  • A 71-year-old patient suffered from a relapse of an atypical lipomatous tumor/well-differentiated liposarcoma with early micronodular (low-grade) dedifferentiation, which had been resected 4 years before.
  • The relapse revealed features of a dedifferentiated liposarcoma with spindle-cell, partly pleomorphic dedifferentiation and osseous metaplasia.
  • Clearly separated from the spindle-cell areas, an extensive homogeneously dense lymphoid (lymphocytic) tumor-component was evident, with relative abrupt transition to the well-differentiated liposarcoma component.
  • Fluorescence in situ hybridization (FISII) analysis revealed no signs of MDM2- and CDK4-gene amplification in the lymphoid areas, although within this mononuclear lymphoid population, large polymorphic nuclei displayed an amplified number of MDM2/CDK4 gene copies, indicating the presence of truly dedifferentiated tumor cells within the lymphoid component.
  • An extensive lymphoid "overgrowth" must be considered within the spectrum of unusual variants and in the differential diagnosis of dedifferentiated liposarcoma.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991843.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


60. Takei H, Dauser R, Su J, Chintagumpala M, Bhattacharjee MB, Jones J, Adesina AM: Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report. J Neurosurg; 2007 Aug;107(2 Suppl):137-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report.
  • A magnetic resonance (MR) image showed a mass lesion originating from the cerebellar vermis with an atypical folial pattern and contrast enhancement.
  • Lhermitte-Duclos disease (LDD) was diagnosed in the patient.
  • Histologically, the tumor showed progressive anaplasia and was most accurately classified as an anaplastic ganglioglioma.
  • This immunohistochemical pattern suggests that the large dysplastic ganglion cells (the gangliocytomatous component) forming the greater part of the lesion were associated with activation of the phosphatidylinositol 3-kinase-PTEN/Akt/mTOR signaling pathway, a feature previously reported in LDD.
  • This case represents the first report of an anaplastic ganglioglioma arising in an LDD-like lesion.
  • [MeSH-minor] Anaplasia / pathology. Anaplasia / psychology. Anaplasia / surgery. Child. Humans. Male


61. Staals EL, Bacchini P, Mercuri M, Bertoni F: Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am; 2007 May;89(5):987-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chondrosarcomas arising in preexisting osteochondromas.
  • BACKGROUND: Dedifferentiated chondrosarcomas that arise in osteochondromas are extremely rare lesions for which very little information on treatment and outcome is available in the literature.
  • The purpose of the present study was to describe the specific clinical, radiographic, and histologic features of this lesion and to evaluate the oncologic outcome after different treatment strategies.
  • Radiographically, ten lesions appeared as a conventional secondary chondrosarcoma arising in an exostosis, whereas eight showed typical signs of dedifferentiation.
  • The dedifferentiated component was considered to be an osteosarcoma in nine cases (including six cases in which it was osteoblastic and three in which it was fibroblastic), a malignant fibrous histiocytoma in eight, and a fibrosarcoma in one.
  • The dedifferentiated component represented an average of 59% (range, 20% to 100%) of the lesion.
  • CONCLUSIONS: Dedifferentiated chondrosarcoma arising in a preexisting osteochondroma is an extremely rare lesion with a poor prognosis.
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473135.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Sims RC, Allaire JC, Gamaldo AA, Edwards CL, Whitfield KE: An examination of dedifferentiation in cognition among African-American older adults. J Cross Cult Gerontol; 2009 Jun;24(2):193-208
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An examination of dedifferentiation in cognition among African-American older adults.
  • There was no evidence of dedifferentiation across increasingly older age groups.
  • The results suggest that a pattern of dedifferentiation of cognitive abilities does not exist within this sample of older African Americans and that the 60-69 year age range may be a critical period for cognitive decline in this population.

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ethn Dis. 1997 Spring-Summer;7(2):127-36 [9386953.001]
  • [Cites] Psychol Aging. 1997 Sep;12(3):410-32 [9308090.001]
  • [Cites] Psychol Aging. 1999 Mar;14(1):18-33 [10224629.001]
  • [Cites] Int J Aging Hum Dev. 1999;48(1):73-9 [10363561.001]
  • [Cites] Psychol Aging. 1999 Jun;14(2):245-63 [10403712.001]
  • [Cites] J Gerontol. 1961 Oct;16:363-9 [13869450.001]
  • [Cites] J Genet Psychol. 1964 Mar;104:3-18 [14128963.001]
  • [Cites] Neuroepidemiology. 2005;24(1-2):8-14 [15459503.001]
  • [Cites] Am Psychol. 1946 Sep;1(9):372-8 [20280373.001]
  • [Cites] J Aging Health. 2000 Feb;12(1):69-89 [10848126.001]
  • [Cites] Psychol Aging. 2002 Jun;17(2):299-320 [12061414.001]
  • [Cites] J Exp Psychol Gen. 2003 Sep;132(3):470-87 [13678379.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2003 Nov;58(6):S327-37 [14614120.001]
  • [Cites] Health Psychol. 2003 Nov;22(6):559-69 [14640852.001]
  • [Cites] Health Psychol. 2003 Nov;22(6):587-91 [14640855.001]
  • [Cites] Psychol Aging. 2003 Dec;18(4):696-713 [14692858.001]
  • [Cites] Psychol Aging. 2003 Dec;18(4):727-45 [14692860.001]
  • [Cites] Psychol Assess. 2004 Mar;16(1):85-9 [15023096.001]
  • [Cites] J Educ Psychol. 1966 Dec;57(6):311-25 [5958121.001]
  • [Cites] J Gerontol. 1975 Jan;30(1):53-5 [1109393.001]
  • [Cites] Hum Dev. 1974;17(5):364-75 [4468927.001]
  • [Cites] Int J Aging Hum Dev. 1980;11(2):135-46 [7203657.001]
  • [Cites] J Gerontol. 1981 May;36(3):323-8 [7229279.001]
  • [Cites] J Gerontol. 1986 Mar;41(2):222-4 [3950349.001]
  • [Cites] Science. 1988 Jul 29;241(4865):540-5 [3399889.001]
  • [Cites] Annu Rev Gerontol Geriatr. 1988;8:3-36 [3148316.001]
  • [Cites] Psychol Aging. 1986 Mar;1(1):55-62 [3267380.001]
  • [Cites] J Gerontol. 1990 Jul;45(4):P145-55 [2365970.001]
  • [Cites] Ethn Dis. 1991 Spring;1(2):135-49 [1842530.001]
  • [Cites] Exp Aging Res. 1992 Autumn-Winter;18(3-4):117-44 [1459160.001]
  • [Cites] Psychosom Med. 1993 Jan-Feb;55(1):51-4 [8446741.001]
  • [Cites] Am Psychol. 1994 Apr;49(4):304-13 [8203802.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 1995 Nov;50(6):P297-306 [7583809.001]
  • [Cites] Psychol Aging. 1997 Mar;12(1):12-21 [9100264.001]
  • [Cites] Psychol Aging. 1998 Dec;13(4):622-30 [9883462.001]
  • (PMID = 18825494.001).
  • [ISSN] 1573-0719
  • [Journal-full-title] Journal of cross-cultural gerontology
  • [ISO-abbreviation] J Cross Cult Gerontol
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG024108-02S1; United States / NIA NIH HHS / AG / R01 AG24108; United States / NIA NIH HHS / AG / R01 AG024108-04; United States / NIA NIH HHS / AG / T32 AG000029-33; United States / NIA NIH HHS / AG / R01 AG024108-02S1; United States / NIA NIH HHS / AG / AG024108-04; United States / NIA NIH HHS / AG / R01 AG024108; United States / NIA NIH HHS / AG / T32 AG00029; United States / NIA NIH HHS / AG / AG000029-33; United States / NIA NIH HHS / AG / T32 AG000029
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS131432; NLM/ PMC2730598
  •  go-up   go-down


63. Bertoni F, Bacchini P, Staals EL, Davidovitz P: Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer; 2005 Jun 1;103(11):2373-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute.
  • BACKGROUND: Dedifferentiated parosteal osteosarcoma (DPOS) is a variant of osteosarcoma in which a high-grade sarcoma coexists with a conventional parosteal osteosarcoma (c-POS), either at presentation (synchronous type) or at the time of recurrence (metachronous type).
  • In 18 patients, radiographic areas of lucency were seen within an otherwise sclerotic lesion.
  • Histologically, the dedifferentiated component was high-grade osteoblastic osteosarcoma in 14 patients, fibroblastic osteosarcoma in 10 patients, giant cell-rich osteosarcoma in 3 patients, and chondroblastic osteosarcoma in 2 patients.
  • One patient died of causes unrelated to the tumor, and another patient died shortly after undergoing resection of a lesion in the skull.
  • CONCLUSIONS: Dedifferentiation occurred in approximately 24% of patients with c-POS.
  • The prognosis for patients with DPOS was better than the prognosis for patients with dedifferentiated central and dedifferentiated peripheral chondrosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Differentiation. Osteosarcoma, Juxtacortical / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852358.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


64. Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F: Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol; 2009 Nov;22(11):1477-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.
  • Liposarcoma represents a unique model insofar as some well-differentiated liposarcomas progress to non-lipogenic, so-called 'dedifferentiated,' forms.
  • The well-differentiated and dedifferentiated family of liposarcomas demonstrates amplification of the chromosome subregion 12q13-q15 with resultant amplification of the MDM2 and CDK4 genes.
  • However, the specific genetic changes that distinguish between well-differentiated and dedifferentiated liposarcomas are less well understood.
  • To study the genetic changes in dedifferentiated liposarcomas, paired well-differentiated and dedifferentiated components of 29 tumors were analyzed separately by array-based comparative genomic hybridization.
  • The genetic changes were compared with clinical presentation, grade of the dedifferentiated component and overexpression of MDM2 and CDK4.
  • Eight tumors (28%) were classified as low-grade dedifferentiation.
  • In four cases (14%), a well-differentiated liposarcoma preceded the presentation of the dedifferentiated tumor by 1-5 years.
  • Using unsupervised hierarchical clustering of copy-number changes, all but two tumors showed close similarities between well-differentiated and dedifferentiated components, and segregated as pairs.
  • Dedifferentiated components had more total amplifications (P=0.008) and a trend for gain at 19q13.2, but no genetic changes were significant in distinguishing between the two components.
  • High-level amplifications of 1p21-32 (n=7, 24%), 1q21-23 (n=9, 31%), 6q23-24 (n=6, 21%) and 12q24 (n=3, 10%) were common, but none significantly correlated with differentiation.
  • [MeSH-major] Cell Differentiation / genetics. Liposarcoma / genetics. Retroperitoneal Neoplasms / genetics. Soft Tissue Neoplasms / genetics

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


65. Damri M, Granot G, Ben-Meir H, Avivi Y, Plaschkes I, Chalifa-Caspi V, Wolfson M, Fraifeld V, Grafi G: Senescing cells share common features with dedifferentiating cells. Rejuvenation Res; 2009 Dec;12(6):435-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senescing cells share common features with dedifferentiating cells.
  • Dedifferentiation signifies the capacity of somatic cells to acquire stem cell-like properties.
  • Dedifferentiation also characterizes the transition of differentiated leaf cells into protoplasts (plant cells devoid of cell walls), a transition accompanied by widespread chromatin decondensation.
  • Transcriptome profiling of dedifferentiating protoplast cells revealed striking similarities with senescing cells; both display a large increase in the expression of genes of specific transcription factor (TF) families, including ANAC, WRKY, bZIP, and C2H2.
  • Further analysis showed that leaves induced to senesce by exposure to dark display characteristic features of dedifferentiating cells, including chromatin decondensation, disruption of the nucleolus, and condensation of rRNA genes.
  • Considering that premature senescence can be induced by various stress conditions both in plant and animal cells, our results suggest that the response of plant and also animal cells to certain stresses converges on cellular dedifferentiation whereby cells first acquire stem cell-like state prior to acquisition of a new cell fate (e.g., reentry into the cell cycle or death).
  • [MeSH-major] Arabidopsis / cytology. Cell Aging / physiology. Cell Dedifferentiation / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20041737.001).
  • [ISSN] 1557-8577
  • [Journal-full-title] Rejuvenation research
  • [ISO-abbreviation] Rejuvenation Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Ribosomal; 0 / Transcription Factors; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


66. Slack JM: Amphibian muscle regeneration--dedifferentiation or satellite cells? Trends Cell Biol; 2006 Jun;16(6):273-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amphibian muscle regeneration--dedifferentiation or satellite cells?
  • Mammalian muscle repair occurs through the mobilization of muscle satellite cells, whereas the new muscle in amphibian appendage regeneration was believed to arise by dedifferentiation of myofibres to form myoblasts.
  • But recent work shows that muscle satellite cells are also involved in amphibian regeneration and the controversy about the reality of muscle dedifferentiation is heating up again.
  • [MeSH-minor] Animals. Cell Differentiation. Myoblasts / physiology. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697200.001).
  • [ISSN] 0962-8924
  • [Journal-full-title] Trends in cell biology
  • [ISO-abbreviation] Trends Cell Biol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300415
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


67. Huang J, Zhang HZ, Zheng L, Zhou J, Jiang ZM: [Clinicopathologic diagnosis of de-differentiated chondrosarcoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Dec;38(12):820-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic diagnosis of de-differentiated chondrosarcoma].
  • OBJECTIVE: To study the clinicopathologic and radiologic features of dedifferentiated chondrosarcoma, focusing on its diagnosis and differential diagnosis.
  • METHOD: Clinical, radiological and pathologic findings of 14 cases of dedifferentiated chondrosarcoma (including biopsy and surgical specimens) were analyzed by hematoxylin and eosin stained sections and immunohistochemistry.
  • An essential histological feature of dedifferentiated chondrosarcoma was an abrupt interface between the low-grade cartilaginous tumor and high-grade anaplastic sarcoma.
  • The most common dedifferentiated components were osteosarcoma, malignant fibrous histocytoma and fibrosarcoma.
  • CONCLUSIONS: Dedifferentiated chondrosarcoma is a rare subtype of chondrosarcoma with poor prognosis, which has different features of clinical manifestation, imaging features and pathological characteristics, compared to conventional chondrosarcoma and chondroblastic osteosarcoma.
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Chondrosarcoma, Mesenchymal / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Osteosarcoma / pathology. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193457.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


68. Grinnell KL, Yang B, Eckert RL, Bickenbach JR: De-differentiation of mouse interfollicular keratinocytes by the embryonic transcription factor Oct-4. J Invest Dermatol; 2007 Feb;127(2):372-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-differentiation of mouse interfollicular keratinocytes by the embryonic transcription factor Oct-4.
  • We also noted an increase in developmental potential caused by Oct-4, with the transfected cells able to differentiate into neuronal cells when exposed to neuroectodermal differentiation medium.
  • These findings suggest that Oct-4 may be the master regulator of the pluripotent state and demonstrate that differentiated somatic cells can be reverted into more developmentally potent cells through the use of a single factor.
  • The latter finding has great implications for therapeutic cell-replacement applications using cells from easily accessible adult tissues, such as the skin.
  • [MeSH-major] Cell Differentiation / physiology. Epidermis / cytology. Keratinocytes / cytology. Octamer Transcription Factor-3 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2007 Feb;127(2):260-2 [17228302.001]
  • (PMID = 16932739.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01-AG20913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Culture Media; 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / NeuN protein, mouse; 0 / Nuclear Proteins; 0 / Octamer Transcription Factor-3; 0 / SOXB1 Transcription Factors; 0 / Sox1 protein, mouse
  •  go-up   go-down


69. Lucas DR, Shukla A, Thomas DG, Patel RM, Kubat AJ, McHugh JB: Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features. Am J Surg Pathol; 2010 Jun;34(6):844-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features.
  • The dedifferentiated component of dedifferentiated liposarcoma shows wide histologic variation including tumors with heterologous differentiation.
  • Myofibroblastic differentiation has been recognized in dedifferentiated liposarcoma.
  • We report the clinicopathologic, immunohistochemical, and molecular finding in 6 cases of dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features treated at our institution.
  • Microscopically, the dedifferentiated component closely resembled or, if taken out of context, was indistinguishable from inflammatory myofibroblastic tumor.
  • One tumor had heterologous osseous differentiation.
  • Well-differentiated liposarcomatous components were present in every tumor.
  • All patients developed locally recurrent or metastatic disease.
  • At last follow-up 2 patients had died of disease and 2 were alive with disease.
  • Dedifferentiated liposarcoma can have prominent inflammatory myofibroblastic tumor-like features, a finding that further expands its histologic spectrum.
  • Awareness of this finding can prevent one from misdiagnosing dedifferentiated liposarcoma as inflammatory myofibroblastic tumor, a much less aggressive neoplasm.

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431481.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. da Cunha IW, Kowalski LP, Soares FA: Dedifferentiated liposarcoma of the oral cavity with angiosarcomatous dedifferentiation. Virchows Arch; 2005 Apr;446(4):456-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma of the oral cavity with angiosarcomatous dedifferentiation.
  • We report a unique case of a 42-year-old woman with a dedifferentiated liposarcoma of the soft tissue of the oral cavity with angiosarcomatous dedifferentiation.
  • Liposarcomas compromising the head and neck region are very unusual, and most of the cases in oral cavity show a well-differentiated pattern.
  • Dedifferentiation in liposarcomas occurs in about 10% of the cases and, when it occurs, the dedifferentiated areas usually resemble high-grade fibrosarcoma or pleomorphic sarcoma.
  • Divergent differentiation might also occur.
  • To the best of our knowledge, there are only nine cases of dedifferentiated liposarcoma of the oral cavity, none of which show an angiosarcomatous dedifferentiation.
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Disease-Free Survival. Female. Humans. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):1-7 [1624288.001]
  • [Cites] J Otolaryngol. 2002 Apr;31(2):125-8 [12019743.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Sep;94(3):333-7 [12324789.001]
  • [Cites] Int J Surg Pathol. 2002 Jan;10(1):75-9 [11927975.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):945-55 [9706974.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):263-6 [11757866.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1020-31 [12379747.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:367-88 [13890373.001]
  • [Cites] J Clin Periodontol. 2001 Feb;28(2):109-12 [11168734.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] Ann Surg. 1944 Jan;119(1):86-107 [17858339.001]
  • [Cites] Cancer. 1960 Sep-Oct;13:932-50 [13696965.001]
  • [Cites] Ann Diagn Pathol. 2000 Aug;4(4):252-66 [10982304.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):92-5 [9950257.001]
  • [Cites] Br J Cancer. 1970 Dec;24(4):696-704 [5503596.001]
  • [Cites] Semin Oncol. 1981 Jun;8(2):185-9 [7196088.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):83-93 [12004355.001]
  • [Cites] Acta Pathol Jpn. 1982 Nov;32(6):933-48 [6297235.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1051-8 [8625207.001]
  • [Cites] Oral Oncol. 2002 Dec;38(8):757-62 [12570054.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):558-61 [10886740.001]
  • (PMID = 15806379.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


71. Ramesh T, Lee SH, Lee CS, Kwon YW, Cho HJ: Somatic cell dedifferentiation/reprogramming for regenerative medicine. Int J Stem Cells; 2009 May;2(1):18-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic cell dedifferentiation/reprogramming for regenerative medicine.
  • The concept of dedifferentiation or reprogramming of a somatic cell into a pluripotent embryonic stem cell-like cell (ES-like cell), which give rise to three germ layers and differentiate various cell types, opens a new era in stem cell biology and provides potential therapeutic modality in regenerative medicine.
  • Here, we outline current dedifferentiation/reprogramming methods and their technical hurdles, and the safety and therapeutic applications of reprogrammed pluripotent stem cells in regenerative medicine.
  • Dedifferentiated/reprogrammed ES-like cells could be a perfect genetic match (autologous or tailored pluripotent stem cells) for future applications.
  • Further studies regarding technical refinements as well as mechanistic analysis of dedifferentiation induction and re-differentiation into specific cell types will provide us with the substantial application of pluripotent stem cells to therapeutic purposes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24855516.001).
  • [ISSN] 2005-3606
  • [Journal-full-title] International journal of stem cells
  • [ISO-abbreviation] Int J Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4021790
  • [Keywords] NOTNLM ; Cell therapy / Dedifferentiation / Regenerative medicine / Reprogramming / Stem cells
  •  go-up   go-down


72. Grafi G: The complexity of cellular dedifferentiation: implications for regenerative medicine. Trends Biotechnol; 2009 Jun;27(6):329-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The complexity of cellular dedifferentiation: implications for regenerative medicine.
  • Cellular dedifferentiation underlies topical issues in biology, such as regeneration and somatic cell nuclear transfer (SCNT), and signifies the withdrawal of cells from a given differentiated state into a 'stem cell'-like state that confers pluripotency.
  • Recently, there has been growing interest in exploiting the dedifferentiation process to obtain autologous stem cell lineages for use in regenerative medicine.
  • However, new insights provided by the study of this process in plants and animals have highlighted the complexity and hazards of cellular dedifferentiation.
  • [MeSH-major] Cell Dedifferentiation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395104.001).
  • [ISSN] 0167-7799
  • [Journal-full-title] Trends in biotechnology
  • [ISO-abbreviation] Trends Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kobayashi C, Izumi T, Ito K, Iwamoto Y, Tsuneyoshi M: Alterations of the RB1 gene in dedifferentiated liposarcoma. Mod Pathol; 2005 Nov;18(11):1461-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of the RB1 gene in dedifferentiated liposarcoma.
  • Dedifferentiated liposarcoma is a malignant adipocytic neoplasm containing a non-lipogenic sarcoma of variable histological grade that arises against the background of a pre-existing well-differentiated liposarcoma.
  • The phenomenon of dedifferentiation is considered to be time-dependent, but the mechanism is not well known.
  • The retinoblastoma protein, encoded by the RB1 gene located at 13q14, is a key regulator of proliferation, development, and differentiation of certain cell types, including adipocytes.
  • In the current study, we investigated the genetic alterations of the RB1 gene, such as mutation (the essential promoter region and the protein-binding pocket domain; exons 20-24) and methylation of the promoter region, in addition to pRB expression and loss of heterozygosity (LOH) status, in two morphologically distinct areas (non-lipogenic dedifferentiated and well-differentiated components) in 27 patients.
  • As a control, 11 undifferentiated high-grade pleomorphic sarcoma/pleomorphic malignant fibrous histiocytoma samples and 11 well-differentiated liposarcoma samples were also evaluated.
  • Dedifferentiated components showed LOH (15/25; 60%) and abnormal retinoblastoma protein expression (18/27; 66.7%) more frequently than noted in the well-differentiated components (3/24; 12.5% and 9/27; 33.3%, respectively).
  • Five and four out of the 27 dedifferentiated components harbored mutations and promoter methylation, respectively, whereas none of these alterations were seen in the well-differentiated components.
  • These results suggest that retinoblastoma protein has a major role to play in dedifferentiation and that a 'two-hit' mechanism is involved in the altered retinoblastoma protein expression in dedifferentiated liposarcoma.

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] .Modern Pathology (2005) 18, 1454-1460. doi:10.1038/modpathol.3800444; published online 20 May 2005.
  • (PMID = 15933756.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  •  go-up   go-down


74. Yoon RS, Benevenia J, Beebe KS, Hameed M: Dedifferentiated liposarcoma of thigh with chondrosarcomatous dedifferentiated component. Am J Orthop (Belle Mead NJ); 2010 Nov;39(11):E114-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for dedifferentiated liposarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma of thigh with chondrosarcomatous dedifferentiated component.
  • Thought to arise de novo, liposarcomas typically are classified into 5 types based on strict morphologic characteristics: well-differentiated, dedifferentiated, myxoid, round cell, and pleomorphic.
  • More specifically, dedifferentiated liposarcoma, a common type most prevalent in the retroperitoneum, often has 2 distinct components, a well-differentiated lipomatous component and a dedifferentiated nonlipomatous component composed of sarcomas, such as myxofibrosarcomas or other spindle-cell sarcomas.
  • However, the case reported in this article is unique-the dedifferentiated component exhibited only chondrosarcomatous differentiation-and it is, to our knowledge, the first such case to be described.

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21623423.001).
  • [ISSN] 1934-3418
  • [Journal-full-title] American journal of orthopedics (Belle Mead, N.J.)
  • [ISO-abbreviation] Am J. Orthop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


75. Boueiz A, Abougergi MS, Noujeim C, Bousamra A, Sfeir P, Zaatari G, Bou-Khalil P: Primary dedifferentiated chondrosarcoma of the lung. South Med J; 2009 Aug;102(8):861-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary dedifferentiated chondrosarcoma of the lung.
  • Extraskeletal dedifferentiated chondrosarcomas (DC) are uncommon tumors that predominantly occur in the head and neck.
  • Moreover, this is the second report of a dedifferentiated variant among all reported cases of primary lung chondrosarcoma.

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593290.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Dornauer K, Söder S, Inwards CY, Bovee JV, Aigner T: Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas. Pathol Int; 2010 May;60(5):365-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas.
  • Dedifferentiated chondrosarcoma is an uncommon mesenchymal neoplasm comprised of two different components, low-grade conventional chondrosarcoma and high-grade non-cartilaginous sarcoma.
  • In order to gain better insight into the biology of this tumor, we investigated a large series of dedifferentiated chondrosarcomas by looking at the composition of the extracellular tumor matrix within each of the distinct histological components.
  • Our results showed that the well-differentiated portion of the tumors showed matrix components largely similar to conventional chondrosarcomas or enchondromas.
  • Our results lend further support to the notion that dedifferentiated chondrosarcoma represents transdifferentiation of a cell towards various blastic mesenchymal cell lineages, most commonly osteoblastic and fibroblastic, but occasionally chondroblastic as well.
  • There was no difference in the clinical outcome of patients with differing high-grade tumor types, emphasizing that grade is a more important predictor of biological behavior than the direction of tumor differentiation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Dedifferentiation. Collagen Type III / metabolism. Collagen Type VI / metabolism. Female. Fluorescent Antibody Technique, Direct. Glycosaminoglycans / metabolism. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518886.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Collagen Type III; 0 / Collagen Type VI; 0 / Extracellular Matrix Proteins; 0 / Glycosaminoglycans
  •  go-up   go-down


77. Uher P, Hüttelová R, Králícková M, Novotný Z, Rokyta Z, Vanderzwalmen P, Zech N: [How can the haematopoietic stem cells from the umbilical cord blood be de-differentiated in vitro? Our first results using the co-cultivation systems]. Ceska Gynekol; 2007 Aug;72(4):280-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How can the haematopoietic stem cells from the umbilical cord blood be de-differentiated in vitro? Our first results using the co-cultivation systems].
  • OBJECTIVE: Aim of this study was to de-differentiate the haematopoietic stem cells (HSCs) that originated from the umbilical cord blood.
  • RESULTS: No de-differentiation was detectable in any our experiment, only the intensity of the HSC cell markers decreased.
  • To reach our goal of in vitro de-differentiation we will need to change our strategy towards a pure human culture system without any animal additives and with cell to cell contact.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ceska Gynekol. 2007 Sep;72(5):368. Zech, N [added]
  • (PMID = 17966609.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


78. Tsyplenkova VG: [Cardiomyocytic dedifferentiation, "hibernation", and apoptosis are possible factors of progressive diabetic cardiomyopathy]. Arkh Patol; 2009 Jul-Aug;71(4):30-3
MedlinePlus Health Information. consumer health - Diabetes Type 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiomyocytic dedifferentiation, "hibernation", and apoptosis are possible factors of progressive diabetic cardiomyopathy].
  • The uncoupled CMCs display the signs of "hibernation", dedifferentiation and atopic degeneration; the neurotransmitters are also prone to apoptosis.
  • [MeSH-minor] Capillaries / pathology. Cell Differentiation. Female. Humans. Male. Middle Aged. Mitochondria, Heart / pathology

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824426.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


79. Cardona DM, Knapik JA, Reith JD: Dedifferentiated parosteal osteosarcoma with giant cell tumor component. Skeletal Radiol; 2008 Apr;37(4):367-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated parosteal osteosarcoma with giant cell tumor component.
  • Dedifferentiated parosteal osteosarcoma is characterized histologically by the admixture of low-grade fibroblastic osteosarcoma and a high-grade component typically resembling conventional osteosarcoma or malignant fibrous histiocytoma.
  • We report an unusual distal femoral dedifferentiated parosteal osteosarcoma in which the dedifferentiated component resembled a giant cell tumor of bone.
  • This phenotype is rarely described in the dedifferentiated component of a dedifferentiated parosteal osteosarcoma.
  • The clinical, radiographic, and pathologic features of this unusual tumor are described to further expand the histologic spectrum of dedifferentiated parosteal osteosarcoma.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):901-10 [3860505.001]
  • [Cites] Skeletal Radiol. 1995 Jan;24(1):76-80 [7709264.001]
  • [Cites] Histopathology. 1995 Jul;27(1):51-5 [7557906.001]
  • [Cites] J Bone Joint Surg Am. 1994 Mar;76(3):366-78 [8126042.001]
  • [Cites] J Bone Joint Surg Am. 1991 Feb;73(2):294-300 [1993724.001]
  • [Cites] Skeletal Radiol. 1999 Sep;28(9):527-31 [10525797.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2373-82 [15852358.001]
  • [Cites] J Bone Joint Surg Br. 1984 May;66(3):313-21 [6586725.001]
  • [Cites] J Bone Joint Surg Am. 1984 Jan;66(1):53-9 [6581170.001]
  • [Cites] Skeletal Radiol. 1996 Jul;25(5):497-500 [8837286.001]
  • [Cites] Skeletal Radiol. 2000 Oct;29(10):597-600 [11127684.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2136-45 [8918422.001]
  • [Cites] Cancer. 1979 Oct;44(4):1495-500 [291468.001]
  • [Cites] J Orthop Sci. 2001;6(3):290-4 [11484126.001]
  • [Cites] Skeletal Radiol. 1998 Oct;27(10 ):574-7 [9840395.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):159-63 [12089726.001]
  • [Cites] Radiology. 1996 Dec;201(3):837-42 [8939240.001]
  • (PMID = 18256826.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Prindull GA, Fibach E: Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells? Exp Hematol; 2007 May;35(5):691-701
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells?
  • Cell dedifferentiation occurs in different cell systems.
  • In spite of a relative paucity of data it seems reasonable to assume that cell dedifferentiation exists in reversible equilibrium with differentiation, to which cells resort in response to intercellular signals.
  • The current literature is indeed compatible with the concept that dedifferentiation is guided by structural rearrangements of nuclear chromatin, directed by epigenetic cell memory information available as silenced genes stored on heterochromatin, and that gene transcription exists in reversible "fluctuating continua" during parental cell cycles.
  • Here, we review the molecular mechanisms of cell dedifferentiation and suggest for hematopoietic development that postnatal hemangioblasts are generated by dedifferentiation of committed hematopoietic stem cells.
  • [MeSH-major] Cell Differentiation / physiology. Hematopoiesis / physiology. Hematopoietic Stem Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577919.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromatin
  • [Number-of-references] 247
  •  go-up   go-down


81. Fossmark R, Zhao CM, Martinsen TC, Kawase S, Chen D, Waldum HL: Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats. APMIS; 2005 Jun;113(6):436-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats.
  • We suggest that ECL cells in hypergastrinemic cotton rats dedifferentiate with time and that the gastric carcinomas may develop from ECL cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996161.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Gastrins; 0 / Pancreatic Hormones; 106477-83-2 / pancreastatin; EC 4.1.1.22 / Histidine Decarboxylase
  •  go-up   go-down


82. He M, Aisner S, Benevenia J, Patterson F, Harrison LE, Hameed M: Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma. Pathol Res Pract; 2009;205(6):386-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
  • The atypical lipomatous tumor (ALT)/well-differentiated liposarcoma (WDLPS) is a locally aggressive subtype of liposarcoma unless dedifferentiation occurs.
  • The aim of this study is to study the role of p16INK4a gene promoter methylation and p16 expression in tumor progression (dedifferentiation) and recurrence of ALT/WDLPS.
  • Four cases of dedifferentiated liposarcomas (DDLPS) and three cases of recurrent well-differentiated liposarcomas (WDLPS) were collected, and methylation status of p16INK4a gene promoter was analyzed using methylation-specific PCR (MSP) on DNA extracted from paraffin blocks. p16 expression was examined by immunohistochemistry on the same blocks.
  • Methylation of p16INK4a gene promoter was seen in the dedifferentiated (DD) components only, in two out of four (2/4, 50%) DDLPS.
  • [MeSH-major] Cell Dedifferentiation / genetics. Epigenesis, Genetic. Genes, p16. Liposarcoma / genetics. Soft Tissue Neoplasms / genetics

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186005.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


83. Ghosh A, Swami R, Sen PK, Dwaka S: Unusual presentation of dedifferentiated liposarcoma as paratesticular mass. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):42-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of dedifferentiated liposarcoma as paratesticular mass.
  • Later on wide excision of tumor was done and histopathology showed dedifferentiated liposarcoma with areas of fibromatosis.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417851.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


84. Kang SK, Park JB, Cha SH: Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev; 2006 Jun;15(3):423-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multipotent, dedifferentiated cancer stem-like cells from brain gliomas.
  • In modern cancer biology, external factors and niches can act on differentiated tissue cells to cause cancer by inducing dedifferentiation of mature adult cells.
  • Recently, we discovered that dedifferentiation of glioma cancer cells alters the expression of mature and neural stem cell (NSC)-related genes, in that cancer cells adjust to the serum-deprived environment and cell-to-cell interaction by down-regulating genes associated with neural mature markers and up-regulating genes that are primitive NSC markers.
  • Neurogenesis of dedifferentiated glioma cancer cells also showed a highly increased neuronal marker associated with highly decreased glial and oligodendrocyte cell markers.
  • After treatment with chemotherapeutic drugs, dedifferentiated cancer cells showed strong drug resistance and continued active cell growth.
  • After grafting to severe combined immunodeficient (SCID) mouse brains, dedifferentiated cancer stem cells migrated and continued active proliferation for more than 4 weeks.
  • We also performed microarray analysis and characterized the gene expression patterns in control cancer cells with dedifferentiated cancer stem-like cells.
  • In this report, we propose that the dedifferentiation process of brain tumor and normal tissue may contribute to the malignancy and aggressiveness of the brain cancer.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Cell Differentiation. Glioma / pathology. Multipotent Stem Cells / cytology

  • Genetic Alliance. consumer health - Brain Stem Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Stem Cells Dev. 2006 Oct;15(5):749
  • (PMID = 16846378.001).
  • [ISSN] 1547-3287
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Messenger
  •  go-up   go-down


85. Yu F, Guo Q, Huang L: [Redifferentiation of the dedifferentiated human articular chondrocytes by the bioreactor culturing]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Aug;20(8):840-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Redifferentiation of the dedifferentiated human articular chondrocytes by the bioreactor culturing].
  • OBJECTIVE: To examine the biological characteristic changes in the dedifferentiated human articular chondrocytes by the bioreactor culturing in vitro.
  • The differentiated phenotype was evaluated by histochemistry or immunohistochemistry.
  • RESULTS: When the monolayer culture was performed without any growth factors, the chondrocytes were rapidly proliferated within 3 passages (average doubling time, 59 h), but at the same time, differentiation was also progressing rapidly.
  • After the 4th passage, most of the cells were differentiated and the proliferation was decreased.
  • With the growth factors (TGF-beta1/FGF-2), the speed of the expansion was accelerated (average doubling time, 47 h), but the speed of the dedifferentiation was slowed down.
  • After 20 passages were performed with the monolayer culture, the dedifferentiated chondrocytes could be redifferentiated when they were cultured for 3 weeks with RCCS.
  • CONCLUSION: The bioreactor culturing of the dedifferentiated human articular chondrocytes can regain the differentiated phenotype and it is a useful method of obtaining the human articular chondrocytes in large amounts and in a differentiated phenotype in vitro.
  • [MeSH-major] Bioreactors. Cell Differentiation. Chondrocytes / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955856.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


86. Fukai R, Fukumura Y, Suzuki K: A dedifferentiated liposarcoma of the anterior mediastinum. Int J Clin Oncol; 2009 Apr;14(2):174-7
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dedifferentiated liposarcoma of the anterior mediastinum.
  • Dedifferentiated liposarcoma was first described in 1979, and its definition has been recently extended.
  • Microscopic examination revealed that the mass was primarily a low-grade, dedifferentiated liposarcoma, with a partial high-grade area.
  • Occurrence of dedifferentiated liposarcoma in the anterior mediastinum is rare.
  • Three years after the surgery, the patient is alive without disease.
  • In lipoma-like, well-differentiated liposarcoma cases, we should consider the possibility of dedifferentiated liposarcoma if a mild, atypical spindle cell component is found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Cardiovasc Surg. 2006 Dec;12(6):425-7 [17228282.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] Radiology. 1985 Nov;157(2):479-83 [4048459.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Pathol Int. 2001 May;51(5):392-5 [11422799.001]
  • [Cites] Thorac Cardiovasc Surg. 1981 Apr;29(2):119-21 [6166071.001]
  • [Cites] Thorax. 1993 Dec;48(12):1276-7 [8303638.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):572-3 [10658747.001]
  • (PMID = 19390952.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Nicolas MM, Tamboli P, Gomez JA, Czerniak BA: Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol; 2010 May;41(5):663-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases.
  • In this article, we supplement the few published articles by describing the clinical and pathologic features of pleomorphic and dedifferentiated leiomyosarcoma from 41 patients (27 women and 14 men) with an age range of 25 to 75 years (mean, 56.5 years), representing the largest cohort reported to date.
  • Based on staining for muscle markers in the pleomorphic component, twenty-three cases were designated as pleomorphic leiomyosarcoma, and 7 cases were designated as dedifferentiated leiomyosarcoma (negative for all muscle markers used).
  • Eleven cases, in which tissue was not available for immunhistochemical stains, the question of pleomorphic versus dedifferentiated leiomyosarcoma could not be answered.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20004935.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Calmodulin-Binding Proteins; 0 / Desmin; 0 / Vimentin
  •  go-up   go-down


88. Candelaria AG, Murray G, File SK, García-Arrarás JE: Contribution of mesenterial muscle dedifferentiation to intestine regeneration in the sea cucumber Holothuria glaberrima. Cell Tissue Res; 2006 Jul;325(1):55-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of mesenterial muscle dedifferentiation to intestine regeneration in the sea cucumber Holothuria glaberrima.
  • Our results show a striking disorganization of the muscle layer together with myocyte dedifferentiation.
  • This dedifferentiation involves nucleic activation, disruptions of intercellular junctions, and the disappearance of cell projections, but more prominently, the loss of the contractile apparatus by the formation and elimination of spindle-like structures.
  • Muscle dedifferentiation can be seen as early as 2 days following evisceration and continues during the next 2 weeks of the regeneration process.
  • Dedifferentiation of myocytes might result in cells that proliferate and give rise to new myocytes.
  • Alternatively, dedifferentiating myocytes could give rise to cells with high nuclear-to-cytoplasmic ratios, with some being eliminated by apoptosis.
  • Our results, together with those in other regeneration models, show that myocyte dedifferentiation is a common event in regeneration processes and that the dedifferentiated cells might play an important role in the formation of the new tissues or organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541286.001).
  • [ISSN] 0302-766X
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR0-3641-01; United States / NIGMS NIH HHS / GM / S06GM08102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  •  go-up   go-down


89. Li H, Fu X, Zhang L, Sun T, Wang J: In vivo dedifferentiation of human epidermal cells. Cell Biol Int; 2007 Nov;31(11):1436-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo dedifferentiation of human epidermal cells.
  • Consistent with our previous study, we herein offer further evidence to demonstrate the dedifferentiation of differentiating epidermal cells into stem cells or stem cells -like in vivo.
  • The results collectively indicated that some of the differentiated cells in engrafted epidermal sheets dedifferentiated into stem cells or stem cells-like in vivo, which offer us new evidence and insights into the dedifferentiation.
  • [MeSH-major] Adult Stem Cells / metabolism. Antigens, CD29 / metabolism. Cell Dedifferentiation. Epidermis / metabolism. Keratins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689109.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 68238-35-7 / Keratins
  •  go-up   go-down


90. Voss MW, Erickson KI, Chaddock L, Prakash RS, Colcombe SJ, Morris KS, Doerksen S, Hu L, McAuley E, Kramer AF: Dedifferentiation in the visual cortex: an fMRI investigation of individual differences in older adults. Brain Res; 2008 Dec 9;1244:121-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiation in the visual cortex: an fMRI investigation of individual differences in older adults.
  • Dedifferentiation, or decreased processing specificity, has been suggested to represent a ubiquitous characteristic of cognitive aging.
  • Our results demonstrated that neural dedifferentiation was not ubiquitous across stimulus categories.
  • Neural dedifferentiation was also relatively stable, across age, in a group of older adults.
  • Older adults with more overall gray matter showed less neural dedifferentiation in the visual cortex.
  • However, regional gray matter volume was not associated with neural dedifferentiation.
  • We illustrate these effects using a discriminability metric, a signal detection theory measure, for neural dedifferentiation that takes into account both magnitude and variance of brain activation.
  • The dedifferentiation measure provides a quantitative means to examine activation patterns and individual difference factors associated with neural dedifferentiation, and to test theories of behavioral dedifferentiation in cognitive aging literature.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848823.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01AG25032; United States / NIA NIH HHS / AG / R01AG25667
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Yaccoby S: The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res; 2005 Nov 1;11(21):7599-606
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
  • CONCLUSIONS: This study indicates that myeloma cells have plasticity expressed by their ability to reprogram, dedifferentiate, and acquire autonomous survival properties.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1996 Jul;94(1):76-81 [8757512.001]
  • [Cites] Hematol Oncol Clin North Am. 1997 Apr;11(2):349-61 [9137974.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Exp Hematol. 1998 Jul;26(7):597-603 [9657134.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3887-97 [9808582.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):530-2 [9827929.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3576-82 [10552969.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):585-96 [10690543.001]
  • [Cites] Blood. 2000 Jul 15;96(2):671-5 [10887133.001]
  • [Cites] Exp Hematol. 2001 Jan;29(1):77-84 [11164108.001]
  • [Cites] Blood. 2001 May 1;97(9):2618-24 [11313250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6 [11562486.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2791-9 [11675353.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3527-33 [11739153.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1972-6 [8634446.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] Blood. 1995 Jan 15;85(2):436-47 [7529064.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1879-82 [8231256.001]
  • [Cites] Blood. 1991 Jun 15;77(12):2688-93 [1675130.001]
  • [Cites] Blood. 1981 Feb;57(2):333-8 [7448427.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1891-7 [15385929.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3534-40 [11739154.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):278-90 [11841428.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3198-204 [12374689.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:214-40 [12446425.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):2991-3003 [12464630.001]
  • [Cites] Clin Exp Metastasis. 2002;19(7):583-91 [12498387.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):287-9 [12543775.001]
  • [Cites] J Bone Miner Res. 2003 Mar;18(3):482-92 [12619933.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3136-41 [12480692.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1436-40 [12684416.001]
  • [Cites] Curr Opin Hematol. 2003 May;10(3):208-13 [12690288.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3019-20 [12810619.001]
  • [Cites] Immunol Rev. 2003 Aug;194:105-11 [12846811.001]
  • [Cites] Immunol Rev. 2003 Aug;194:196-206 [12846816.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):95-105 [12953802.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5438-45 [14500379.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1463-7 [14565645.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1477-81 [14565647.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):175-9 [14722607.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Blood Cells Mol Dis. 2004 Mar-Apr;32(2):293-301 [15003821.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2016-23 [15026338.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2892-9 [15070660.001]
  • [Cites] Haematologica. 2004 May;89(5):547-51 [15136217.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2484-91 [15187021.001]
  • (PMID = 16278377.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093897; United States / NCI NIH HHS / CA / CA-93897
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Interleukin-6; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; 7S5I7G3JQL / Dexamethasone; EC 3.1.3.48 / Antigens, CD45; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS10141; NLM/ PMC1592552
  •  go-up   go-down


92. Kaimoto T, Yasuda O, Ohishi M, Mogi M, Takemura Y, Suhara T, Ogihara T, Fukuo K, Rakugi H: Nifedipine inhibits vascular smooth muscle cell dedifferentiation via downregulation of Akt signaling. Hypertension; 2010 Aug;56(2):247-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nifedipine inhibits vascular smooth muscle cell dedifferentiation via downregulation of Akt signaling.
  • Calcium is an essential signaling molecule that controls vascular smooth muscle cell (VSMC) contraction, proliferation, and differentiation.
  • Here, we show that the calcium antagonist nifedipine inhibits VSMC dedifferentiation in vitro and in vivo.
  • Differentiated VSMCs cultured on laminin-coated dishes were transferred to laminin-free dishes to induce dedifferentiation.
  • Induction of dedifferentiation resulted in the upregulation of nonmuscle myosin heavy chain expression, a marker of dedifferentiation, and the downregulation of smooth muscle myosin heavy chain expression, a marker of differentiation.
  • The inhibitory effect of the downregulation of Akt signaling by dominant-negative Akt on the induction of VSMC dedifferentiation in the intima was identical to that of nifedipine.
  • In contrast, upregulation of Akt signaling by transfection of the cells with a constitutively active Akt reversed the nifedipine-induced inhibition of VSMC dedifferentiation.
  • In conclusion, nifedipine inhibits VSMC dedifferentiation by suppressing Akt signaling, thereby preventing neointimal thickening.
  • [MeSH-major] Cell Differentiation / drug effects. Muscle, Smooth, Vascular / cytology. Muscle, Smooth, Vascular / physiology. Nifedipine / pharmacology. Proto-Oncogene Proteins c-akt / physiology

  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530298.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


93. Chitteti BR, Peng Z: Proteome and phosphoproteome dynamic change during cell dedifferentiation in Arabidopsis. Proteomics; 2007 May;7(9):1473-500
The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteome and phosphoproteome dynamic change during cell dedifferentiation in Arabidopsis.
  • Cell dedifferentiation is a cell fate switching process in which a differentiated cell reverts to a status with competence for cell division and organ regeneration like an embryonic stem cell.
  • Although the phenomenon of cell dedifferentiation has been known for over two and a half centuries in plants, little is known of the underlying mechanisms.
  • Here, we have established the proteome map of Arabidopsis cotyledons and investigated the dynamic change of the cotyledon proteome in the time course of cell dedifferentiation.
  • Among the 353 distinct genes, corresponding to 500 2-DE gel protein spots identified with high confidence, 12% have over twofold differential regulations within the first 48 h of induction of cell dedifferentiation.
  • Among the 53 identified putative phosphoproteins, nine are differentially regulated during cell dedifferentiation.
  • These studies have provided significant new insight into protein and phosphoprotein differential expression during cell dedifferentiation in plants.
  • [MeSH-major] Arabidopsis / cytology. Arabidopsis Proteins / metabolism. Cell Differentiation / physiology. Phosphoproteins / metabolism. Proteome / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17407188.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Phosphoproteins; 0 / Proteome
  •  go-up   go-down


94. Rozeman LB, de Bruijn IH, Bacchini P, Staals EL, Bertoni F, Bovée JV, Hogendoorn PC: Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. Mod Pathol; 2009 Nov;22(11):1489-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes.
  • Dedifferentiated peripheral chondrosarcoma is a rare subtype of chondrosarcoma arising superimposed on the cartilage cap of a preexisting osteochondroma.
  • It consists of two clearly defined components, a low-grade malignant, well-differentiated cartilage component and a high-grade non-cartilaginous sarcoma.
  • Sixteen well-characterized dedifferentiated peripheral chondrosarcomas were immunohistochemically analyzed for parathyroid hormone-like hormone (PTHLH)-BCL-2, fibroblastic growth factor (FGF), and transforming growth factor-beta signaling molecules, as well as matrix molecules and p53, comparing the chondrogenic component of dedifferentiated peripheral chondrosarcomas with the anaplastic component and with previously published data obtained from conventional grade I and II secondary peripheral chondrosarcomas.
  • In the anaplastic component, various lines of differentiation could be found (collagen I (6/16), CD31 (1/16), smooth muscle actin (12/16), muscle-specific actin (12/16) and desmin (2/9)).
  • Compared with the anaplastic component, the chondrogenic component of dedifferentiated peripheral chondrosarcomas shows more often expression of cyclin D1 (P=0.05), p53 (P=0.008), plasminogen activator inhibitor 1 (PAI-1) (P=0.005), and CD44 (P=0.030).
  • Compared with secondary peripheral chondrosarcomas, more samples were positive in the chondrogenic component of dedifferentiated peripheral chondrosarcomas for FGF signaling (FGF receptor 3 P=0.000; bFGF P=0.003) and CD44 (P=0.000).
  • Lower expression of BCL-2 (P=0.025) and absence of CD44v3 (P=0.000), a splice variant of CD44, was observed in the chondrogenic component of dedifferentiated peripheral chondrosarcomas compared with secondary peripheral chondrosarcomas.
  • With regard to clinical data, PAI-1 expression in the chondrogenic component of dedifferentiated peripheral chondrosarcomas correlated with better survival (P=0.019).
  • In conclusion, in the chondrogenic component of dedifferentiated peripheral chondrosarcomas, FGF signaling pathway is active, whereas PTHLH signaling seems to be low/downregulated.
  • Interestingly, although the chondrogenic component of dedifferentiated peripheral chondrosarcoma is CD44+/CD44v3-, secondary peripheral chondrosarcomas is CD44-/CD44v3+, which suggest different splicing (preference).
  • The prognostic value of PAI-1 in dedifferentiated peripheral chondrosarcomas might also be of interest for the more common dedifferentiated central chondrosarcomas.
  • [MeSH-major] Bone Neoplasms / metabolism. Cartilage, Articular / metabolism. Cell Differentiation. Chondrosarcoma / metabolism. Neoplasm Proteins / metabolism


95. Kacem K, Sercombe C, Hammami M, Vicaut E, Sercombe R: Sympathectomy causes aggravated lesions and dedifferentiation in large rabbit atherosclerotic arteries without involving nitric oxide. J Vasc Res; 2006;43(3):289-305
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sympathectomy causes aggravated lesions and dedifferentiation in large rabbit atherosclerotic arteries without involving nitric oxide.
  • Segments of basilar (BA) and femoral (FA) arteries were studied histochemically, to evaluate differentiation (anti-desmin, anti-vimentin, anti-h-caldesmon, and nuclear dye), by confocal microscopy, and by in vitro myography.
  • Thus, sympathectomy aggravates the tendency for FA SMCs to migrate and dedifferentiate, increasing atherosclerotic lesions, without decreasing NO activity, but has only minor effects on BAs.
  • [MeSH-major] Atherosclerosis / pathology. Basilar Artery / pathology. Cell Differentiation. Femoral Artery / pathology. Sympathectomy, Chemical
  • [MeSH-minor] Acetylcholine / pharmacology. Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Hypercholesterolemia / pathology. Male. Nitric Oxide / metabolism. Nitric Oxide Synthase / antagonists & inhibitors. Nitric Oxide Synthase / metabolism. Nitroarginine / pharmacology. Oxidopamine. Rabbits. Tunica Intima / pathology. Tunica Media / pathology. Vasodilator Agents / pharmacology

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16651846.001).
  • [ISSN] 1018-1172
  • [Journal-full-title] Journal of vascular research
  • [ISO-abbreviation] J. Vasc. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Vasodilator Agents; 2149-70-4 / Nitroarginine; 31C4KY9ESH / Nitric Oxide; 8HW4YBZ748 / Oxidopamine; EC 1.14.13.39 / Nitric Oxide Synthase; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


96. Jopling C, Sleep E, Raya M, Martí M, Raya A, Izpisúa Belmonte JC: Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature; 2010 Mar 25;464(7288):606-9
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation.
  • Here we use this system to show that regenerated heart muscle cells are derived from the proliferation of differentiated cardiomyocytes.
  • Furthermore, we show that proliferating cardiomyocytes undergo limited dedifferentiation characterized by the disassembly of their sarcomeric structure, detachment from one another and the expression of regulators of cell-cycle progression.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Biol. 2006 Aug;4(8):e260 [16869712.001]
  • [Cites] Int J Cardiol. 2007 Jan 2;114(1):118-20 [16338014.001]
  • [Cites] Dev Dyn. 2007 Apr;236(4):1025-35 [17326133.001]
  • [Cites] Cell. 2009 Jul 23;138(2):257-70 [19632177.001]
  • [Cites] J Cardiovasc Med (Hagerstown). 2010 May;11(5):369-80 [20179605.001]
  • [Cites] J Mol Cell Cardiol. 2007 Apr;42(4):706-21 [17362983.001]
  • [Cites] Cardiovasc Res. 2001 Aug 1;51(2):230-40 [11470462.001]
  • [Cites] Anat Embryol (Berl). 2002 Jun;205(3):235-44 [12107494.001]
  • [Cites] Science. 2002 Dec 13;298(5601):2188-90 [12481136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11889-95 [12909711.001]
  • [Cites] Nature. 2004 May 6;429(6987):41-6 [15129273.001]
  • [Cites] J Exp Zool. 1974 Feb;187(2):249-53 [4813417.001]
  • [Cites] Int J Dev Biol. 1996 Aug;40(4):719-25 [8877445.001]
  • [Cites] N Engl J Med. 1998 Jul 16;339(3):173-81 [9664095.001]
  • [Cites] Genes Dev. 2005 May 15;19(10):1175-87 [15870258.001]
  • [Cites] Cell. 2006 Nov 3;127(3):607-19 [17081981.001]
  • [Cites] J Cell Sci. 2006 Nov 15;119(Pt 22):4719-29 [17077121.001]
  • [CommentIn] Circ Res. 2010 Sep 3;107(5):570-2 [20814025.001]
  • (PMID = 20336145.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL088293-01A1; United States / NHLBI NIH HHS / HL / R33 HL088293; United States / NHLBI NIH HHS / HL / R33 HL088293-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ NIHMS178186; NLM/ PMC2846535
  •  go-up   go-down


97. Darville MI, Eizirik DL: Notch signaling: a mediator of beta-cell de-differentiation in diabetes? Biochem Biophys Res Commun; 2006 Jan 27;339(4):1063-8
MedlinePlus Health Information. consumer health - Diabetes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling: a mediator of beta-cell de-differentiation in diabetes?
  • Microarray analyses of insulin-producing cells exposed to interleukin-1beta+interferon-gamma showed decreased expression of genes related to beta-cell-differentiated functions and increased expression of members of the Notch signaling pathway.
  • Thus, activation of the Notch pathway inhibits differentiated functions in dividing but not in terminally differentiated beta-cells.
  • [MeSH-minor] Animals. Cell Differentiation. Cells, Cultured. Insulin / metabolism. Insulinoma / metabolism. Insulinoma / pathology. Male. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337608.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Insulin; 0 / Receptors, Notch
  •  go-up   go-down


98. Parakh RS, Zawar MP, Gadgil PA, Kaujalagi NS: Dedifferentiated liposarcoma of the retro-peritoneum: histologically low-grade type. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):353-5
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated liposarcoma of the retro-peritoneum: histologically low-grade type.
  • A dedifferentiated liposarcoma of the retro-peritoneum of a 45-year-old female is described in this case report.
  • It showed dedifferentiation into a histological low-grade type and thus defies the traditional definition of dedifferentiated liposarcoma.
  • The mass showed a dedifferentiated focus different in color from the surrounding tumor and containing areas of necrosis and hemorrhage.
  • The sections from the dedifferentiated part of the tumor appeared predominantly as benign spindle cell component on histology but the tumor was infiltrating into the kidney.
  • In the retro-peritoneum, a lipoma-like well-differentiated liposarcoma with spindle cell component, like the present tumor, which shows dedifferentiation, should not be overlooked.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551557.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


99. Skawran B, Steinemann D, Becker T, Buurman R, Flik J, Wiese B, Flemming P, Kreipe H, Schlegelberger B, Wilkens L: Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Mod Pathol; 2008 Dec;21(12):1479-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma.
  • Dedifferentiation of hepatocellular carcinoma implies aggressive clinical behavior and is associated with an increasing number of genomic alterations, eg deletion of 13q.
  • Therefore this study compares array comparative genomic hybridization and whole genome gene expression data of 23 well, moderately, or poorly dedifferentiated hepatocellular carcinoma, using unsupervised hierarchical clustering.
  • Dedifferentiated carcinoma clearly branched off from well and moderately differentiated carcinoma (P<0.001 chi(2)-test).
  • Within the dedifferentiated group, 827 genes were upregulated and 33 genes were downregulated.
  • A total of 6 genes (BIC, CPNE1, RBPMS, RFC4, RPSA, TOP2A) were among the 20 most significantly upregulated genes both in dedifferentiated carcinoma and in carcinoma with loss of 13q.
  • Of 33 downregulated genes in the dedifferentiated subgroup, 4 metallothioneins had the lowest fold change, most probably mediated through inactivation of C/EBPalpha by the PI3K/AKT cascade.
  • In conclusion dedifferentiation of hepatocellular carcinoma is associated with upregulation of genes involved in cell-cycle control and proliferation.
  • [MeSH-minor] Adult. Aged. Cell Differentiation / genetics. Cell Proliferation. Child. Female. Humans. Male. MicroRNAs / genetics. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820673.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


100. Schulze-Tanzil G: Activation and dedifferentiation of chondrocytes: implications in cartilage injury and repair. Ann Anat; 2009 Oct;191(4):325-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation and dedifferentiation of chondrocytes: implications in cartilage injury and repair.
  • This technique requires sufficient expansion of differentiated autologous chondrocytes, which were then seeded on suitable biodegradable three-dimensional (3D) matrices to preform an extracellular cartilage matrix (ECM) before implantation into the defect.
  • Cell expansion is accompanied by chondrocyte dedifferentiation, whereby substantial changes occur at multiple levels of chondrocyte synthetic profiles: including the ECM, cell surface receptors and cytoskeletal proteins.
  • Since these dedifferentiated chondrocytes produce a non-specific mechanically inferior ECM, they are not suitable for MACT.
  • 3D cultures are means of inducing and maintaining chondrocyte (re)differentiation and to preform ECM.
  • The combination of MACT with anabolic growth factors and anti-inflammatory strategies using anti-inflammatory mediators might be useful for stabilizing the differentiated chondrocyte phenotype, to support neocartilage formation and inhibit post-traumatic cartilage inflammation and hence, the development of secondary OA.

  • MedlinePlus Health Information. consumer health - Cartilage Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19541465.001).
  • [ISSN] 1618-0402
  • [Journal-full-title] Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
  • [ISO-abbreviation] Ann. Anat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Proteoglycans; 9007-34-5 / Collagen
  • [Number-of-references] 59
  •  go-up   go-down






Advertisement